mercury dibromide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	mercury dibromide	go back to main search page
Accession:	CHEBI:49639	browse the term
Definition:	A mercury coordination entity composed of mercury and bromine with the formula HgBr2.
Synonyms:	exact_synonym:	mercury(2+) bromide; mercury(II) bromide
	related_synonym:	DIBROMOMERCURY; Formula=Br2Hg; HgBr2; InChI=1S/2BrH.Hg/h2*1H;/q;;+2/p-2; InChIKey=NGYIMTKLQULBOO-UHFFFAOYSA-L; SMILES=Br[Hg]Br; mercuric bromide; mercury bromide
	alt_id:	CHEBI:33212; CHEBI:49638
	xref:	CAS:7789-47-1; Gmelin:277818
	xref_mesh:	MESH:C042720
	xref:	PDBeChem:HG2; PMID:15074688; Reaxys:8127939; Wikipedia:Mercury(II)_bromide

show annotations for term's descendants Sort by:
Rat (1003) Mouse (1013) Human (1075) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1013)

mercury dibromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 0610030E20 gene

decreases expression
multiple interactions

mercuric bromide results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:72,324,017...72,330,145
Ensembl chr 6:72,324,300...72,330,131

G

RIKEN cDNA 0610040J01 gene

increases expression

mercuric bromide results in increased expression of C4ORF19 mRNA

NCBI chr 5:63,969,833...64,056,968
Ensembl chr 5:63,969,706...64,056,968

G

RIKEN cDNA 2310030G06 gene

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA

NCBI chr 9:50,650,991...50,657,827
Ensembl chr 9:50,650,991...50,657,836

G

RIKEN cDNA 2510009E07 gene

decreases expression
multiple interactions

mercuric bromide results in decreased expression of C3ORF70 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:21,467,795...21,513,415
Ensembl chr16:21,467,795...21,513,415

G

RIKEN cDNA 2610528J11 gene

increases expression
multiple interactions

mercuric bromide results in increased expression of C1ORF210 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1ORF210 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:118,384,207...118,387,422
Ensembl chr 4:118,384,196...118,387,425

G

RIKEN cDNA 3110082J24 gene

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TM4SF18 mRNA

NCBI chr 5:30,308,573...30,311,095
Ensembl chr 5:30,308,582...30,311,084

G

RIKEN cDNA 9130008F23 gene

decreases expression

mercuric bromide results in decreased expression of C6ORF141 mRNA

NCBI chr17:41,186,373...41,191,449
Ensembl chr17:41,186,373...41,191,450

G

alpha-1-B glycoprotein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of A1BG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA

PMID:26272509 PMID:27188386

NCBI chr15:60,789,438...60,793,119
Ensembl chr15:60,768,708...60,794,861

G

ATP-binding cassette, sub-family B member 6

increases expression
multiple interactions

mercuric bromide results in increased expression of ABCB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036

G

ATP-binding cassette, sub-family C member 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ABCC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

ATP binding cassette subfamily G member 2 (Junior blood group)

increases expression
multiple interactions

mercuric bromide results in increased expression of ABCG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

abhydrolase domain containing 14A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:106,317,250...106,328,402
Ensembl chr 9:106,317,253...106,324,877

G

abhydrolase domain containing 3

increases expression
multiple interactions

mercuric bromide results in increased expression of ABHD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:10,644,411...10,706,784
Ensembl chr18:10,642,092...10,706,771

G

acid phosphatase 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA

NCBI chr 9:104,165,439...104,214,921
Ensembl chr 9:104,165,450...104,214,947

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA

NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088

G

actin, gamma 2, smooth muscle, enteric

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTG2 mRNA

NCBI chr 6:83,489,891...83,513,233
Ensembl chr 6:83,489,887...83,513,247

G

actinin alpha 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ACTN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:4,911,244...4,927,937
Ensembl chr19:4,911,244...4,927,937

G

a disintegrin and metallopeptidase domain 28

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA

NCBI chr14:68,842,447...68,893,338
Ensembl chr14:68,843,476...68,893,291

G

ADAM metallopeptidase domain 9

increases expression
multiple interactions

mercuric bromide results in increased expression of ADAM9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:25,439,627...25,507,138
Ensembl chr 8:25,439,627...25,506,943

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ADAMTS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001

G

ADAM metallopeptidase with thrombospondin type 1 motif 12

increases expression
multiple interactions

mercuric bromide results in increased expression of ADAMTS12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS12 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:11,064,781...11,349,321
Ensembl chr15:11,064,876...11,349,317

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA

NCBI chr11:50,492,912...50,698,400
Ensembl chr11:50,492,911...50,698,400

G

ADAM metallopeptidase with thrombospondin type 1 motif 20

decreases expression

mercuric bromide results in decreased expression of ADAMTS20 mRNA

NCBI chr15:94,166,177...94,329,966
Ensembl chr15:94,168,044...94,363,299

G

adenylate cyclase 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ADCY2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:68,768,162...69,147,719
Ensembl chr13:68,768,162...69,147,660

G

adenylate cyclase activating polypeptide 1 receptor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ADCYAP1R1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:55,428,486...55,478,440
Ensembl chr 6:55,428,963...55,478,436

G

adhesion G protein-coupled receptor G2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ADGRG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:159,173,315...159,281,072
Ensembl chr X:159,173,686...159,281,066

G

adhesion G protein-coupled receptor G6

multiple interactions
increases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
mercuric bromide results in increased expression of ADGRG6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:14,278,327...14,421,467
Ensembl chr10:14,278,327...14,421,403

G

adrenomedullin

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADM mRNA

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

actin filament associated protein 1-like 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of AFAP1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:56,900,786...57,017,021
Ensembl chr19:56,900,793...56,996,660

G

alpha fetoprotein

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFP mRNA

NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766

G

angiotensin II receptor, type 1a

increases expression

mercuric bromide results in increased expression of AGTR1 mRNA

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

adherens junction associated protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of AJAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:153,457,678...153,568,313
Ensembl chr 4:153,457,678...153,567,268

G

aldo-keto reductase family 1, member C18

increases expression
multiple interactions

mercuric bromide results in increased expression of AKR1C3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldo-keto reductase family 1, member C20

increases expression
multiple interactions

mercuric bromide results in increased expression of AKR1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344

G

aldo-keto reductase family 1, member C21

increases expression
multiple interactions

mercuric bromide results in increased expression of AKR1C2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540

G

activated leukocyte cell adhesion molecule

increases expression
multiple interactions

mercuric bromide results in increased expression of ALCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA

PMID:26272509 PMID:27188386

NCBI chr16:52,069,359...52,273,444
Ensembl chr16:52,069,359...52,274,437

G

aldehyde dehydrogenase family 1, subfamily A3

increases expression
multiple interactions

mercuric bromide results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:66,040,640...66,077,225
Ensembl chr 7:66,040,638...66,077,265

G

aldehyde dehydrogenase 1 family, member L2

increases expression
multiple interactions

mercuric bromide results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:83,320,386...83,370,008
Ensembl chr10:83,323,314...83,370,004

G

aldehyde dehydrogenase 3 family, member B3

increases expression
multiple interactions

mercuric bromide results in increased expression of ALDH3B2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH3B2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:4,008,733...4,022,419
Ensembl chr19:4,008,645...4,022,103

G

ALK and LTK ligand 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ALKAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:30,934,323...30,943,855
Ensembl chr12:30,934,321...30,943,853

G

alpha-kinase 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ALPK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALPK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:65,398,600...65,526,959
Ensembl chr18:65,398,600...65,527,137

G

alpha 1 microglobulin/bikunin precursor

increases expression
multiple interactions

mercuric bromide results in increased expression of AMBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:63,061,512...63,072,409
Ensembl chr 4:63,061,512...63,073,036

G

APC membrane recruitment 2

increases expression
multiple interactions

mercuric bromide results in increased expression of AMER2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:60,615,141...60,625,642
Ensembl chr14:60,610,708...60,625,646

G

adhesion molecule with Ig like domain 2

increases expression
multiple interactions

mercuric bromide results in increased expression of AMIGO2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:97,141,955...97,145,168
Ensembl chr15:97,142,006...97,145,168

G

ankyrin 1, erythroid

increases expression
multiple interactions

mercuric bromide results in increased expression of ANK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:23,464,852...23,640,517
Ensembl chr 8:23,464,860...23,640,513

G

ankyrin repeat domain 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ANKRD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:36,089,365...36,097,244
Ensembl chr19:36,089,361...36,097,499

G

ankyrin repeat domain 33B

increases expression
multiple interactions

mercuric bromide results in increased expression of ANKRD33B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD33B mRNA

PMID:26272509 PMID:27188386

NCBI chr15:31,278,328...31,370,446
Ensembl chr15:31,291,624...31,367,872

G

anthrax toxin receptor 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ANTXR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:87,110,835...87,312,757
Ensembl chr 6:87,110,835...87,312,803

G

annexin A1

increases expression
multiple interactions

mercuric bromide results in increased expression of ANXA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

annexin A2

increases expression
multiple interactions

mercuric bromide results in increased expression of ANXA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077

G

annexin A3

increases expression
multiple interactions

mercuric bromide results in increased expression of ANXA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:96,941,257...96,993,825
Ensembl chr 5:96,941,198...96,993,825

G

annexin A4

increases expression
multiple interactions

mercuric bromide results in increased expression of ANXA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566

G

annexin A9

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA

NCBI chr 3:95,203,404...95,222,491
Ensembl chr 3:95,203,407...95,214,487

G

aldehyde oxidase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of AOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:58,068,963...58,145,569
Ensembl chr 1:58,069,090...58,145,572

G

amyloid beta precursor protein binding family A member 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of APBA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:64,151,444...64,403,620
Ensembl chr 7:64,151,454...64,403,626

G

adenomatosis polyposis coli down-regulated 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of APCDD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:63,055,398...63,086,886
Ensembl chr18:63,055,302...63,094,250

G

apolipoprotein A-I

increases expression
multiple interactions

mercuric bromide results in increased expression of APOA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764

G

apolipoprotein A-II

increases expression
multiple interactions

mercuric bromide results in increased expression of APOA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ARAP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:62,759,788...62,923,874
Ensembl chr 5:62,759,788...62,923,502

G

Rho GTPase activating protein 18

increases expression
multiple interactions

mercuric bromide results in increased expression of ARHGAP18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:26,648,363...26,794,644
Ensembl chr10:26,629,417...26,794,644

G

Rho, GDP dissociation inhibitor beta

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGDIB mRNA

NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897

G

Rho guanine nucleotide exchange factor 25

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ARHGEF25 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:127,018,390...127,025,952
Ensembl chr10:127,018,394...127,025,952

G

CDC42 guanine nucleotide exchange factor 9

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ARHGEF9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:94,092,536...94,240,801
Ensembl chr X:94,092,541...94,240,462

G

AT-rich interaction domain 5B

increases expression
multiple interactions

mercuric bromide results in increased expression of ARID5B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA

PMID:26272509 PMID:27188386

NCBI chr10:67,928,353...68,114,596
Ensembl chr10:67,928,350...68,114,570

G

ADP-ribosylation factor-like 9

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ARL9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:77,146,054...77,158,806
Ensembl chr 5:77,151,902...77,158,453

G

arrestin, beta 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ARRB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:99,184,356...99,255,979
Ensembl chr 7:99,184,673...99,255,978

G

arrestin domain containing 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ARRDC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:71,287,773...71,293,173
Ensembl chr 8:71,287,773...71,292,364

G

ADP-ribosyltransferase 2b

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TIGD7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TIGD7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:101,224,936...101,234,790
Ensembl chr 7:101,226,177...101,234,807

G

aristaless related homeobox

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ARX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA

PMID:26272509 PMID:27188386

NCBI chr X:92,330,113...92,341,963
Ensembl chr X:92,330,051...92,341,963

G

activating signal cointegrator 1 complex subunit 3

increases expression
multiple interactions

mercuric bromide results in increased expression of ASCC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:50,468,756...50,727,300
Ensembl chr10:50,468,765...50,727,581

G

anti-silencing function 1A histone chaperone

increases expression
multiple interactions

mercuric bromide results in increased expression of ASF1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA

PMID:26272509 PMID:27188386

NCBI chr10:53,473,057...53,485,321
Ensembl chr10:53,472,853...53,485,321

G

acid-sensing ion channel 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ASIC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:99,568,090...99,599,011
Ensembl chr15:99,568,249...99,599,011

G

asparagine synthetase

increases expression
multiple interactions

mercuric bromide results in increased expression of ASNS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254

G

aspartate beta-hydroxylase domain containing 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ASPHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:126,545,159...126,548,754
Ensembl chr 7:126,544,739...126,548,754

G

astrotactin 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:158,189,647...158,519,351
Ensembl chr 1:158,189,843...158,519,351

G

activating transcription factor 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

G

atlastin GTPase 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ATL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:7,471,178...7,515,974
Ensembl chr19:7,471,405...7,517,039

G

ATPase, class V, type 10D

increases expression
multiple interactions

mercuric bromide results in increased expression of ATP10D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP10D mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:72,360,672...72,456,114
Ensembl chr 5:72,360,672...72,456,118

G

ATPase, H+ transporting, lysosomal V1 subunit C1

increases expression
multiple interactions

mercuric bromide results in increased expression of ATP6V1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V1C1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:38,662,096...38,692,688
Ensembl chr15:38,662,177...38,692,690

G

ATPase phospholipid transporting 8A1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ATP8A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:67,775,482...68,004,822
Ensembl chr 5:67,775,483...68,004,777

G

ATPase, class I, type 8B, member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338

G

B9 protein domain 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of B9D1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:61,395,970...61,403,757
Ensembl chr11:61,395,970...61,403,757

G

BCL2-associated athanogene 2

increases expression
multiple interactions

mercuric bromide results in increased expression of BAG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:33,784,565...33,796,831
Ensembl chr 1:33,784,565...33,796,876

G

BCL2-associated athanogene 3

increases expression
multiple interactions

mercuric bromide results in increased expression of BAG3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705

G

BMP and activin membrane-bound inhibitor

increases expression
multiple interactions

mercuric bromide results in increased expression of BAMBI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA

PMID:26272509 PMID:27188386

NCBI chr18:3,507,011...3,516,404
Ensembl chr18:3,507,923...3,516,404

G

Bardet-Biedl syndrome 9

increases expression
multiple interactions

mercuric bromide results in increased expression of BBS9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:22,386,819...22,799,579
Ensembl chr 9:22,387,011...22,799,576

G

butyrylcholinesterase

decreases expression

mercuric bromide results in decreased expression of BCHE mRNA

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

BCL11 transcription factor A

increases expression
multiple interactions

mercuric bromide results in increased expression of BCL11A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA

PMID:26272509 PMID:27188386

NCBI chr11:24,026,498...24,123,558
Ensembl chr11:24,028,056...24,124,123

G

BCL2 like 11

decreases expression
multiple interactions

mercuric bromide results in decreased expression of BCL2L11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467

G

beta-carotene oxygenase 1

multiple interactions
decreases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA
mercuric bromide results in decreased expression of BCO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:117,822,590...117,860,459
Ensembl chr 8:117,822,593...117,860,459

G

brain derived neurotrophic factor

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDNF mRNA

NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352

G

BEN domain containing 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of BEND4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:67,549,490...67,585,471
Ensembl chr 5:67,549,490...67,585,653

G

BEN domain containing 6

increases expression
multiple interactions

mercuric bromide results in increased expression of BEND6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:33,891,133...33,946,925
Ensembl chr 1:33,891,133...33,946,897

G

basic helix-loop-helix family, member e40

increases expression
multiple interactions

mercuric bromide results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886

G

bone morphogenetic protein 4

increases expression
multiple interactions

mercuric bromide results in increased expression of BMP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126

G

bone morphogenetic protein 5

increases expression
multiple interactions

mercuric bromide results in increased expression of BMP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:75,682,647...75,807,598
Ensembl chr 9:75,682,646...75,807,592

G

bone morphogenetic protein 6

increases expression
multiple interactions

mercuric bromide results in increased expression of BMP6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

bone morphogenetic protein 7

increases expression
multiple interactions

mercuric bromide results in increased expression of BMP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

basonuclin zinc finger protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of BNC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:81,616,401...81,642,047
Ensembl chr 7:81,616,401...81,642,055

G

BCL2/adenovirus E1B 19kD interacting protein like

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA

NCBI chr 3:95,148,587...95,158,504
Ensembl chr 3:95,148,582...95,158,504

G

BOC cell adhesion associated, oncogene regulated

decreases expression
multiple interactions

mercuric bromide results in decreased expression of BOC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA

PMID:26272509 PMID:27188386

NCBI chr16:44,305,408...44,379,233
Ensembl chr16:44,305,412...44,379,260

G

B-box and SPRY domain containing

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA

NCBI chr 4:62,398,248...62,415,537
Ensembl chr 4:62,398,290...62,415,535

G

bone marrow stromal cell antigen 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of BST2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:71,986,899...71,990,116
Ensembl chr 8:71,986,899...71,990,100

G

BTG anti-proliferation factor 2

increases expression
multiple interactions

mercuric bromide results in increased expression of BTG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858

G

BTG anti-proliferation factor 3

increases expression

mercuric bromide results in increased expression of BTG3 mRNA

NCBI chr16:78,156,748...78,174,069
Ensembl chr16:78,129,525...78,174,080

G

complement component 1, s subcomponent 1

increases expression
multiple interactions

mercuric bromide results in increased expression of C1S mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:124,507,303...124,519,340
Ensembl chr 6:124,507,304...124,519,318

G

calcium binding protein 39-like

increases expression
multiple interactions

mercuric bromide results in increased expression of CAB39L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA

PMID:26272509 PMID:27188386

NCBI chr14:59,678,400...59,786,353
Ensembl chr14:59,678,421...59,823,213

G

cache domain containing 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CACHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:100,633,870...100,861,741
Ensembl chr 4:100,633,872...100,886,417

G

calcium channel, voltage-dependent, beta 2 subunit

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA

NCBI chr 2:14,608,672...14,993,622
Ensembl chr 2:14,607,899...14,992,719

G

cell adhesion molecule 2

increases expression
multiple interactions

mercuric bromide results in increased expression of CADM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:66,452,302...67,417,825
Ensembl chr16:66,452,307...67,417,796

G

calbindin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CALB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:15,881,264...15,906,709
Ensembl chr 4:15,881,264...15,908,064

G

calcium/calmodulin-dependent protein kinase II, delta

increases expression
multiple interactions

mercuric bromide results in increased expression of CAMK2D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:126,389,136...126,639,975
Ensembl chr 3:126,389,951...126,639,975

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CAMK2N1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:138,182,459...138,187,437
Ensembl chr 4:138,181,625...138,187,434

G

carbonic anhydrase 13

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA

NCBI chr 3:14,706,787...14,728,062
Ensembl chr 3:14,706,787...14,728,062

G

carbonic anhydrase 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:84,848,580...84,856,880
Ensembl chr11:84,848,612...84,856,870

G

cysteinyl-tRNA synthetase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CARS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:143,110,967...143,153,827
Ensembl chr 7:143,110,967...143,153,827

G

caspase 3

decreases activity

mercuric bromide results in decreased activity of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

increases expression
multiple interactions

mercuric bromide results in increased expression of CASP8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caveolin 1, caveolae protein

increases expression
multiple interactions

mercuric bromide results in increased expression of CAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451

G

caveolin 2

increases expression
multiple interactions

mercuric bromide results in increased expression of CAV2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:17,281,184...17,289,129
Ensembl chr 6:17,281,184...17,289,114

G

coiled-coil and C2 domain containing 1B

increases expression
multiple interactions

mercuric bromide results in increased expression of CC2D1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:108,477,105...108,495,801
Ensembl chr 4:108,477,137...108,491,320

G

cell cycle activator and apoptosis regulator 2

decreases expression

mercuric bromide results in decreased expression of CCAR2 mRNA

NCBI chr14:70,375,617...70,391,272
Ensembl chr14:70,375,613...70,391,260

G

collagen and calcium binding EGF domains 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CCBE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:66,189,926...66,424,909
Ensembl chr18:66,178,373...66,435,812

G

coiled-coil domain containing 102A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CCDC102A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:95,629,497...95,644,726
Ensembl chr 8:95,629,497...95,644,726

G

coiled-coil domain containing 113

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CFAP263 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP263 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:96,260,684...96,285,516
Ensembl chr 8:96,260,713...96,285,518

G

coiled-coil domain containing 136

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:29,396,296...29,426,954
Ensembl chr 6:29,396,308...29,426,987

G

coiled-coil domain containing 177

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:80,802,221...80,807,489
Ensembl chr12:80,800,817...80,807,461

G

cholecystokinin B receptor

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CCKBR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105

G

cellular communication network factor 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CCN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736

G

cellular communication network factor 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA

NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581

G

cyclin G2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090

G

CD40 antigen

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CD40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868

G

CD44 antigen

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CD82 antigen

decreases expression

mercuric bromide results in decreased expression of CD82 mRNA

NCBI chr 2:93,249,447...93,293,295
Ensembl chr 2:93,249,456...93,293,485

G

CD9 antigen

increases expression
multiple interactions

mercuric bromide results in increased expression of CD9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:125,437,229...125,471,723
Ensembl chr 6:125,437,229...125,471,754

G

CDC14 cell division cycle 14B

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA

NCBI chr13:64,337,085...64,423,670
Ensembl chr13:64,337,082...64,423,104

G

cadherin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CDH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 10

increases expression
multiple interactions

mercuric bromide results in increased expression of CDH10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:18,818,763...19,014,883
Ensembl chr15:18,819,033...19,014,322

G

cadherin 13

increases expression
multiple interactions

mercuric bromide results in increased expression of CDH13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH13 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:119,010,150...120,051,668
Ensembl chr 8:119,010,472...120,051,660

G

cadherin 3

increases expression
multiple interactions

mercuric bromide results in increased expression of CDH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:107,237,484...107,283,543
Ensembl chr 8:107,237,523...107,283,929

G

cadherin 6

increases expression
multiple interactions

mercuric bromide results in increased expression of CDH6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:13,028,785...13,176,493
Ensembl chr15:13,028,787...13,173,761

G

cadherin 7, type 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CDH7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:109,909,967...110,073,002
Ensembl chr 1:109,910,161...110,067,887

G

cadherin 9

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CDH9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:16,728,641...16,857,224
Ensembl chr15:16,728,842...16,857,180

G

cyclin dependent kinase 19

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CDK19 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:40,225,283...40,359,814
Ensembl chr10:40,215,560...40,359,814

G

cyclin dependent kinase 6

increases expression
multiple interactions

mercuric bromide results in increased expression of CDK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:3,391,004...3,581,008
Ensembl chr 5:3,391,485...3,581,008

G

cyclin dependent kinase inhibitor 1A

increases expression
multiple interactions

mercuric bromide results in increased expression of CDKN1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 2A

increases expression
multiple interactions

mercuric bromide results in increased expression of CDKN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890

G

CDP-diacylglycerol synthase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CDS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:101,913,001...101,971,724
Ensembl chr 5:101,912,996...101,971,724

G

CCAAT/enhancer binding protein beta

increases expression
multiple interactions

mercuric bromide results in increased expression of CEBPB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

CCAAT/enhancer binding protein delta

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

CUGBP, Elav-like family member 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:81,295,061...81,318,564
Ensembl chr10:81,295,061...81,318,543

G

centrosomal protein 85-like

increases expression
multiple interactions

mercuric bromide results in increased expression of CEP85L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA

PMID:26272509 PMID:27188386

NCBI chr10:53,149,537...53,256,765
Ensembl chr10:53,149,539...53,256,043

G

cilia and flagella associated protein 300

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CFAP300 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:8,021,673...8,042,876
Ensembl chr 9:8,021,673...8,042,824

G

cilia and flagella associated protein 91

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:38,118,116...38,162,222
Ensembl chr16:38,118,116...38,162,505

G

cilia and flagella associated protein 96

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CFAP96 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP96 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:46,387,980...46,428,290
Ensembl chr 8:46,406,643...46,428,477

G

cystic fibrosis transmembrane conductance regulator

increases expression
multiple interactions

mercuric bromide results in increased expression of CFTR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

ChaC, cation transport regulator 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA

NCBI chr 2:119,181,723...119,184,807
Ensembl chr 2:119,181,710...119,184,862

G

choline kinase alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of CHKA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:3,901,585...3,944,368
Ensembl chr19:3,901,773...3,944,369

G

charged multivesicular body protein 4C

increases expression
multiple interactions

mercuric bromide results in increased expression of CHMP4C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP4C mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:10,432,033...10,456,065
Ensembl chr 3:10,431,967...10,493,916

G

chondrolectin

increases expression
multiple interactions

mercuric bromide results in increased expression of CHODL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA

PMID:26272509 PMID:27188386

NCBI chr16:78,727,729...78,748,624
Ensembl chr16:78,727,836...78,748,621

G

cysteine and histidine rich domain containing 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA

NCBI chr 9:18,203,563...18,225,296
Ensembl chr 9:18,203,421...18,228,738

G

chordin-like 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CHRDL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:142,068,670...142,177,282
Ensembl chr X:142,068,670...142,177,258

G

ciliary microtubule associated protein 1B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CIMAP1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIMAP1B mRNA

PMID:26272509 PMID:27188386

NCBI chr15:89,261,652...89,263,817
Ensembl chr15:89,261,652...89,263,790

G

ciliary microtubule associated protein 3

increases expression
multiple interactions

mercuric bromide results in increased expression of CIMAP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:105,904,273...105,921,962
Ensembl chr 3:105,904,273...105,921,962

G

claudin 11

increases expression
multiple interactions

mercuric bromide results in increased expression of CLDN11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:31,204,069...31,218,475
Ensembl chr 3:31,204,069...31,218,473

G

claudin 18

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA

NCBI chr 9:99,572,849...99,599,320
Ensembl chr 9:99,571,514...99,599,320

G

claudin 4

increases expression
multiple interactions

mercuric bromide results in increased expression of CLDN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:134,973,977...134,975,788
Ensembl chr 5:134,973,973...134,975,788

G

claudin 7

increases expression
multiple interactions

mercuric bromide results in increased expression of CLDN7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:69,855,605...69,858,712
Ensembl chr11:69,855,605...69,858,711

G

C-type lectin domain family 18, member A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CLEC18A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:111,796,128...111,819,056
Ensembl chr 8:111,785,552...111,819,058

G

CLN8 transmembrane ER and ERGIC protein

increases expression
multiple interactions

mercuric bromide results in increased expression of CLN8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:14,931,335...14,951,720
Ensembl chr 8:14,931,335...14,951,720

G

cornifelin

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CNFN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:25,067,041...25,069,149
Ensembl chr 7:25,067,045...25,069,149

G

connector enhancer of kinase suppressor of Ras 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:156,604,426...156,827,454
Ensembl chr X:156,604,432...156,826,290

G

CCR4-NOT transcription complex, subunit 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CNOT4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:34,999,000...35,110,646
Ensembl chr 6:34,999,000...35,110,659

G

contactin 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:132,437,163...132,470,989
Ensembl chr 1:132,437,165...132,470,994

G

contactin associated protein-like 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CNTNAP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:64,883,994...65,051,845
Ensembl chr13:64,883,996...65,051,769

G

collagen, type XI, alpha 1

increases expression
multiple interactions

mercuric bromide results in increased expression of COL11A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367

G

collagen, type XII, alpha 1

increases expression
multiple interactions

mercuric bromide results in increased expression of COL12A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL12A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:79,506,269...79,628,423
Ensembl chr 9:79,506,273...79,626,113

G

collagen, type I, alpha 1

increases expression
multiple interactions

mercuric bromide results in increased expression of COL1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

increases expression
multiple interactions

mercuric bromide results in increased expression of COL1A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type III, alpha 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type VI, alpha 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA

NCBI chr 1:90,694,582...90,771,710
Ensembl chr 1:90,693,645...90,771,693

G

collagen, type VIII, alpha 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A1 mRNA

NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100

G

collagen beta(1-O)galactosyltransferase 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:152,275,485...152,386,942
Ensembl chr 1:152,275,581...152,386,446

G

COP9 signalosome subunit 8

decreases expression
multiple interactions

mercuric bromide results in decreased expression of COPS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:90,531,147...90,541,063
Ensembl chr 1:90,530,703...90,541,063

G

carboxypeptidase E

increases expression
multiple interactions

mercuric bromide results in increased expression of CPE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:65,045,576...65,146,143
Ensembl chr 8:65,045,576...65,146,088

G

cytoplasmic polyadenylation element binding protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of CPEB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:43,382,692...43,447,067
Ensembl chr 5:43,390,513...43,447,067

G

carnitine palmitoyltransferase 1a, liver

increases expression
multiple interactions

mercuric bromide results in increased expression of CPT1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA

PMID:26272509 PMID:27188386

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

carboxypeptidase X, M14 family member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of CPXM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:131,634,416...131,756,483
Ensembl chr 7:131,634,416...131,756,468

G

cellular repressor of E1A-stimulated genes 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CREG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:165,591,327...165,602,878
Ensembl chr 1:165,591,315...165,602,877

G

cysteine rich transmembrane BMP regulator 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CRIM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:78,507,602...78,684,021
Ensembl chr17:78,507,677...78,684,021

G

crystallin, beta A4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:112,394,358...112,411,411
Ensembl chr 5:112,394,359...112,400,384

G

colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage)

increases expression
multiple interactions

mercuric bromide results in increased expression of CSF2RA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:61,205,629...61,221,141
Ensembl chr19:61,212,395...61,216,867

G

chondroitin sulfate proteoglycan 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CSPG5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:110,072,851...110,091,644
Ensembl chr 9:110,072,851...110,091,644

G

cysteine and glycine-rich protein 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA

NCBI chr 1:135,614,650...135,679,970
Ensembl chr 1:135,647,799...135,679,970

G

CTD small phosphatase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CTDSP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:74,430,625...74,436,444
Ensembl chr 1:74,430,668...74,436,444

G

cystathionine gamma lyase

increases expression
multiple interactions

mercuric bromide results in increased expression of CTH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714

G

collagen triple helix repeat containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:38,940,327...38,950,516
Ensembl chr15:38,940,327...38,950,516

G

catenin delta 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:30,172,680...31,029,490
Ensembl chr15:30,172,739...31,029,487

G

cullin 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA

NCBI chr 1:80,242,640...80,318,426
Ensembl chr 1:80,242,640...80,318,197

G

cutA divalent cation tolerance homolog-like

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUTALP mRNA

NCBI chr 2:34,764,408...34,782,145
Ensembl chr 2:34,764,408...34,782,144

G

C-X-C motif chemokine ligand 14

increases expression
multiple interactions

mercuric bromide results in increased expression of CXCL14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364

G

C-X-C motif chemokine receptor 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of CXCR4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030

G

cytochrome b5 type A (microsomal)

increases expression
multiple interactions

mercuric bromide results in increased expression of CYB5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA

PMID:26272509 PMID:27188386

NCBI chr18:84,869,463...84,897,996
Ensembl chr18:84,856,829...84,897,996

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CYP1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

mercuric bromide results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytohesin 3

increases expression
multiple interactions

mercuric bromide results in increased expression of CYTH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:143,608,202...143,696,005
Ensembl chr 5:143,608,202...143,696,005

G

disabled 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DAB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041

G

doublecortin-like kinase 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DCLK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:86,693,457...86,828,292
Ensembl chr 3:86,693,458...86,828,159

G

doublecortin

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DCX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA

PMID:26272509 PMID:27188386

NCBI chr X:142,638,838...142,716,392
Ensembl chr X:142,638,838...142,716,307

G

DNA-damage inducible transcript 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

discoidin domain receptor family, member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of DDR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331

G

DENN domain containing 1B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DENND1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:138,891,447...139,103,781
Ensembl chr 1:138,891,173...139,106,698

G

diacylglycerol kinase, iota

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DGKI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:36,814,316...37,281,034
Ensembl chr 6:36,822,957...37,277,119

G

dehydrogenase/reductase 11

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DHRS11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:84,711,547...84,719,880
Ensembl chr11:84,711,682...84,719,820

G

DEAH-box helicase 15

decreases expression

mercuric bromide results in decreased expression of DHX15 mRNA

NCBI chr 5:52,307,545...52,347,888
Ensembl chr 5:52,307,545...52,347,856

G

divergent protein kinase domain 1C

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA

PMID:26272509 PMID:27188386

NCBI chr18:84,737,133...84,762,820
Ensembl chr18:84,737,361...84,758,561

G

deleted in liver cancer 1

increases expression
multiple interactions

mercuric bromide results in increased expression of DLC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:37,034,893...37,420,343
Ensembl chr 8:37,034,905...37,420,297

G

delta like canonical Notch ligand 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DLL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:15,587,616...15,597,275
Ensembl chr17:15,587,616...15,597,134

G

distal-less homeobox 3

increases expression
multiple interactions

mercuric bromide results in increased expression of DLX3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:95,010,943...95,016,122
Ensembl chr11:95,010,945...95,016,122

G

distal-less homeobox 5

increases expression
multiple interactions

mercuric bromide results in increased expression of DLX5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:6,877,801...6,882,068
Ensembl chr 6:6,877,805...6,882,085

G

distal-less homeobox 6

increases expression
multiple interactions

mercuric bromide results in increased expression of DLX6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:6,863,272...6,867,965
Ensembl chr 6:6,863,334...6,868,568

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA

NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282

G

DnaJ heat shock protein family (Hsp40) member C6

increases expression
multiple interactions

mercuric bromide results in increased expression of DNAJC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:101,353,751...101,499,996
Ensembl chr 4:101,353,828...101,499,996

G

dedicator of cytokinesis 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DOCK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:21,711,476...21,764,006
Ensembl chr 9:21,711,156...21,763,931

G

dedicator of cytokinesis 7

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DOCK7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:98,824,669...99,019,190
Ensembl chr 4:98,824,908...99,009,152

G

dedicator of cytokinesis 8

decreases expression

mercuric bromide results in decreased expression of DOCK8 mRNA

NCBI chr19:24,976,753...25,179,796
Ensembl chr19:24,976,898...25,179,796

G

dedicator of cytokinesis 9

increases expression
multiple interactions

mercuric bromide results in increased expression of DOCK9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:121,772,026...122,038,465
Ensembl chr14:121,779,458...122,035,249

G

DEAQ RNA-dependent ATPase

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DQX1 mRNA

NCBI chr 6:83,034,728...83,044,294
Ensembl chr 6:83,034,825...83,044,299

G

dopamine receptor D4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DRD4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377

G

desmocollin 3

increases expression
multiple interactions

mercuric bromide results in increased expression of DSC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:20,093,987...20,135,465
Ensembl chr18:20,093,987...20,135,408

G

desmoplakin

increases expression
multiple interactions

mercuric bromide results in increased expression of DSP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA

PMID:26272509 PMID:27188386

NCBI chr13:38,335,357...38,382,553
Ensembl chr13:38,335,270...38,382,553

G

dual serine/threonine and tyrosine protein kinase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of DSTYK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:132,345,127...132,394,697
Ensembl chr 1:132,345,293...132,394,696

G

dystrobrevin alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of DTNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTNA mRNA

PMID:26272509 PMID:27188386

NCBI chr18:23,443,063...23,792,776
Ensembl chr18:23,548,192...23,792,772

G

Dppa2 upstream binding RNA

increases expression
multiple interactions

mercuric bromide results in increased expression of DUBR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUBR mRNA

PMID:26272509 PMID:27188386

NCBI chr16:50,547,114...50,553,136
Ensembl chr16:50,530,732...50,553,159

G

dual specificity phosphatase 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

dual specificity phosphatase 10

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA

NCBI chr 1:183,766,575...183,807,833
Ensembl chr 1:183,745,499...183,807,833

G

dual specificity phosphatase 14

increases expression
multiple interactions

mercuric bromide results in increased expression of DUSP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:83,938,859...83,960,016
Ensembl chr11:83,938,867...83,960,087

G

dual specificity phosphatase 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP2 mRNA

NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296

G

dual specificity phosphatase 5

increases expression
multiple interactions

mercuric bromide results in increased expression of DUSP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862

G

dual specificity phosphatase 8

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA

NCBI chr 7:141,633,224...141,649,799
Ensembl chr 7:141,633,227...141,649,580

G

ELL associated factor 2

increases expression
multiple interactions

mercuric bromide results in increased expression of EAF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:36,613,246...36,695,275
Ensembl chr16:36,613,246...36,695,365

G

early B cell factor 1

decreases expression

mercuric bromide results in decreased expression of EBF1 mRNA

NCBI chr11:44,502,738...44,898,923
Ensembl chr11:44,508,144...44,898,918

G

endothelin 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin receptor type B

increases expression

mercuric bromide results in increased expression of EDNRB mRNA

NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838

G

EEF1A lysine methyltransferase 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of EEF1AKMT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:132,429,186...132,454,376
Ensembl chr 7:132,429,186...132,454,402

G

EF-hand domain (C-terminal) containing 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA

NCBI chr X:16,998,288...17,186,291
Ensembl chr X:16,998,288...17,185,607

G

ephrin A1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA

NCBI chr 3:89,179,037...89,188,258
Ensembl chr 3:89,179,040...89,188,449

G

ephrin A2

decreases expression

mercuric bromide results in decreased expression of EFNA2 mRNA

NCBI chr10:80,015,316...80,025,844
Ensembl chr10:80,015,316...80,025,844

G

epidermal growth factor

increases expression
multiple interactions

mercuric bromide results in increased expression of EGF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

EGF-like domain 7

decreases expression
multiple interactions

mercuric bromide results in decreased expression of EGFL7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:26,471,095...26,482,694
Ensembl chr 2:26,470,026...26,483,132

G

EP300 interacting inhibitor of differentiation 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of EID3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:82,702,460...82,703,764
Ensembl chr10:82,702,460...82,703,764

G

eukaryotic translation initiation factor 4E member 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:99,599,008...99,669,834
Ensembl chr 6:99,602,096...99,643,732

G

E74-like factor 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA

NCBI chr 1:135,181,312...135,186,210
Ensembl chr 1:135,181,313...135,186,306

G

E74 like ETS transcription factor 4

increases expression
multiple interactions

mercuric bromide results in increased expression of ELF4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:47,499,926...47,552,009
Ensembl chr X:47,499,923...47,552,009

G

E74-like factor 5

increases expression
multiple interactions

mercuric bromide results in increased expression of ELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:103,242,443...103,281,334
Ensembl chr 2:103,242,033...103,281,334

G

ELK3, member of ETS oncogene family

increases expression
multiple interactions

mercuric bromide results in increased expression of ELK3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:93,083,277...93,147,021
Ensembl chr10:93,083,276...93,146,997

G

ELMO/CED-12 domain containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:53,818,741...53,882,628
Ensembl chr 9:53,818,741...53,882,585

G

epithelial membrane protein 1

increases expression

mercuric bromide results in increased expression of EMP1 mRNA

NCBI chr 6:135,339,548...135,360,171
Ensembl chr 6:135,339,543...135,360,171

G

endosulfine alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of ENSA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:95,532,291...95,539,428
Ensembl chr 3:95,532,304...95,539,413

G

EGF domain specific O-linked N-acetylglucosamine transferase

increases expression
multiple interactions

mercuric bromide results in increased expression of EOGT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:97,086,977...97,128,445
Ensembl chr 6:97,086,985...97,126,143

G

endothelial PAS domain protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of EPAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838

G

erythrocyte membrane protein band 4.1 like 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA

NCBI chr17:69,382,642...69,596,986
Ensembl chr17:69,382,678...69,596,984

G

erythrocyte membrane protein band 4.1 like 5

increases expression
multiple interactions

mercuric bromide results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:119,472,762...119,576,826
Ensembl chr 1:119,472,767...119,576,730

G

epithelial cell adhesion molecule

increases expression
multiple interactions

mercuric bromide results in increased expression of EPCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA

PMID:26272509 PMID:27188386

NCBI chr17:87,943,407...87,958,555
Ensembl chr17:87,943,407...87,958,557

G

ependymin related 1

increases expression
multiple interactions

mercuric bromide results in increased expression of EPDR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:19,775,878...19,804,000
Ensembl chr13:19,775,876...19,804,097

G

Eph receptor A2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA

NCBI chr 4:141,028,532...141,056,695
Ensembl chr 4:141,028,551...141,056,695

G

Eph receptor B1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of EPHB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:101,799,327...102,231,892
Ensembl chr 9:101,799,327...102,231,892

G

Eph receptor B2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:136,374,850...136,563,637
Ensembl chr 4:136,374,850...136,563,299

G

epsin 3

increases expression
multiple interactions

mercuric bromide results in increased expression of EPN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:94,380,425...94,390,800
Ensembl chr11:94,380,425...94,390,800

G

EPS8-like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of EPS8L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:140,918,824...140,942,933
Ensembl chr 7:140,918,793...140,942,933

G

epithelial stromal interaction 1

increases expression
multiple interactions

mercuric bromide results in increased expression of EPSTI1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:78,141,679...78,240,096
Ensembl chr14:78,141,679...78,240,097

G

endoplasmic reticulum aminopeptidase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ERAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:74,787,692...74,841,321
Ensembl chr13:74,787,687...74,841,320

G

glutamate rich 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ERICH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:14,075,051...14,140,393
Ensembl chr 8:14,077,561...14,140,301

G

glutamate rich 5

increases expression
multiple interactions

mercuric bromide results in increased expression of ERICH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERICH5 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:34,453,458...34,474,038
Ensembl chr15:34,453,451...34,474,038

G

endoplasmic reticulum oxidoreductase 1 beta

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA

NCBI chr13:12,580,701...12,624,422
Ensembl chr13:12,580,755...12,626,285

G

endoplasmic reticulum protein 27

increases expression
multiple interactions

mercuric bromide results in increased expression of ERP27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:136,884,312...136,899,465
Ensembl chr 6:136,884,309...136,899,178

G

epithelial splicing regulatory protein 1

increases expression

mercuric bromide results in increased expression of ESRP1 mRNA

NCBI chr 4:11,331,933...11,386,783
Ensembl chr 4:11,331,933...11,386,783

G

epithelial splicing regulatory protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ESRP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:106,856,658...106,863,825
Ensembl chr 8:106,856,951...106,863,606

G

enhancer trap locus 4

increases expression
multiple interactions

mercuric bromide results in increased expression of KIAA1217 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:19,915,018...20,815,346
Ensembl chr 2:19,914,591...20,815,524

G

ethanolamine kinase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of ETNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:143,112,592...143,154,272
Ensembl chr 6:143,112,947...143,178,033

G

E26 avian leukemia oncogene 1, 5' domain

increases expression
multiple interactions

mercuric bromide results in increased expression of ETS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:32,547,501...32,669,116
Ensembl chr 9:32,547,517...32,669,116

G

EvC ciliary complex subunit 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA

NCBI chr 5:37,495,801...37,582,399
Ensembl chr 5:37,495,843...37,582,399

G

coagulation factor II thrombin receptor like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of F2RL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:95,833,428...95,839,276
Ensembl chr13:95,833,361...95,839,247

G

coagulation factor III

increases expression
multiple interactions

mercuric bromide results in increased expression of F3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697

G

coagulation factor V

increases expression
multiple interactions

mercuric bromide results in increased expression of F5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846

G

family with sequence similarity 110, member C

increases expression
multiple interactions

mercuric bromide results in increased expression of FAM110C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA

PMID:26272509 PMID:27188386

NCBI chr12:31,123,967...31,129,939
Ensembl chr12:31,123,860...31,130,250

G

family with sequence similarity 124, member A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FAM124A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:62,793,186...62,845,935
Ensembl chr14:62,793,186...62,845,935

G

family with sequence similarity 13, member C

increases expression
multiple interactions

mercuric bromide results in increased expression of FAM13C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA

PMID:26272509 PMID:27188386

NCBI chr10:70,274,981...70,394,566
Ensembl chr10:70,276,311...70,394,566

G

family with sequence similarity 149, member A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FAM149A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:45,789,752...45,835,328
Ensembl chr 8:45,789,754...45,835,328

G

family with sequence similarity 162, member B

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA

NCBI chr10:51,461,510...51,466,686
Ensembl chr10:51,461,512...51,466,613

G

family with sequence similarity 169, member A

increases expression
multiple interactions

mercuric bromide results in increased expression of FAM169A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM169A mRNA

PMID:26272509 PMID:27188386

NCBI chr13:97,203,795...97,266,801
Ensembl chr13:97,203,794...97,267,521

G

family with sequence similarity 222, member A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FAM222A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:114,706,312...114,751,281
Ensembl chr 5:114,706,077...114,751,281

G

family with sequence similarity 241, member A

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA

NCBI chr 3:127,663,337...127,689,972
Ensembl chr 3:127,662,707...127,689,973

G

family with sequence similarity 89, member A

increases expression
multiple interactions

mercuric bromide results in increased expression of FAM89A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:125,466,996...125,478,605
Ensembl chr 8:125,466,996...125,478,571

G

Fas cell surface death receptor

increases expression
multiple interactions

mercuric bromide results in increased expression of FAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA

PMID:26272509 PMID:27188386

NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172

G

filamin binding LIM protein 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA

NCBI chr 4:141,303,373...141,333,351
Ensembl chr 4:141,303,373...141,333,407

G

f-box protein 9

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FBXO9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:77,988,781...78,016,347
Ensembl chr 9:77,988,781...78,016,347

G

ferrochelatase

increases expression
multiple interactions

mercuric bromide results in increased expression of FECH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA

PMID:26272509 PMID:27188386

NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322

G

fasciculation and elongation protein zeta 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FEZ1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:36,732,694...36,790,220
Ensembl chr 9:36,733,160...36,790,220

G

Fez family zinc finger 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FEZF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:10,121,561...10,130,771
Ensembl chr14:10,121,574...10,127,669

G

fibrinogen beta chain

increases expression
multiple interactions

mercuric bromide results in increased expression of FGB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:82,949,553...82,957,170
Ensembl chr 3:82,947,448...82,957,170

G

fibroblast growth factor 9

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA

NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177

G

fibroblast growth factor receptor 2

decreases expression

mercuric bromide results in decreased expression of FGFR2 mRNA

NCBI chr 7:129,764,181...129,868,538
Ensembl chr 7:129,764,181...132,725,079

G

formin homology 2 domain containing 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FHOD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:24,841,445...25,266,564
Ensembl chr18:24,841,680...25,266,558

G

four jointed box 1

decreases expression

mercuric bromide results in decreased expression of FJX1 mRNA

NCBI chr 2:102,279,711...102,282,137
Ensembl chr 2:102,279,711...102,282,844

G

FK506 binding protein 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FKBP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501

G

Friend leukemia integration 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLI1 mRNA

NCBI chr 9:32,333,500...32,454,292
Ensembl chr 9:32,333,500...32,454,157

G

filamin, beta

increases expression
multiple interactions

mercuric bromide results in increased expression of FLNB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA

PMID:26272509 PMID:27188386

NCBI chr14:14,518,185...14,651,852
Ensembl chr14:14,518,185...14,651,816

G

filamin C, gamma

increases expression

mercuric bromide results in increased expression of FLNC mRNA

NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882

G

FMS-like tyrosine kinase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of FLT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821

G

fibronectin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of FN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

fibronectin type III domain containing 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FNDC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:31,449,589...31,453,279
Ensembl chr 5:31,449,586...31,453,424

G

fibronectin type III domain containing 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FNDC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:129,030,672...129,038,386
Ensembl chr 4:129,030,477...129,038,386

G

fos-like antigen 1

increases expression
multiple interactions

mercuric bromide results in increased expression of FOSL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974

G

fos-like antigen 2

increases expression
multiple interactions

mercuric bromide results in increased expression of FOSL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:32,292,599...32,315,184
Ensembl chr 5:32,293,145...32,315,186

G

forkhead box C1

increases expression
multiple interactions

mercuric bromide results in increased expression of FOXC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:31,990,629...31,994,618
Ensembl chr13:31,990,616...31,996,459

G

forkhead box C2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA

NCBI chr 8:121,842,910...121,845,634
Ensembl chr 8:121,842,910...121,845,634

G

forkhead box L2

increases expression
multiple interactions

mercuric bromide results in increased expression of FOXL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:98,837,495...98,840,601
Ensembl chr 9:98,837,341...98,840,596

G

Fras1 related extracellular matrix protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of FREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:82,816,157...82,970,743
Ensembl chr 4:82,816,164...82,970,576

G

FERM domain containing 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of FRMD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:73,931,454...74,120,451
Ensembl chr 4:73,931,679...74,120,451

G

frizzled-related protein

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA

NCBI chr 2:80,242,314...80,277,740
Ensembl chr 2:80,242,314...80,277,969

G

ferritin heavy polypeptide 1

increases expression
multiple interactions

mercuric bromide results in increased expression of FTH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462

G

ferritin light polypeptide 1

increases expression
multiple interactions

mercuric bromide results in increased expression of FTL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

Ftx transcript, Xist regulator, non-protein coding

increases expression

mercuric bromide results in increased expression of FTX mRNA

NCBI chr X:102,604,516...102,667,360
Ensembl chr X:102,604,513...102,667,396

G

frizzled class receptor 10

decreases expression

mercuric bromide results in decreased expression of FZD10 mRNA

NCBI chr 5:128,678,170...128,681,157
Ensembl chr 5:128,677,908...128,681,157

G

GABA type A receptor associated protein like 1

increases expression

mercuric bromide results in increased expression of GABARAPL1 mRNA

NCBI chr 6:129,510,155...129,519,294
Ensembl chr 6:129,510,123...129,519,309

G

gamma-aminobutyric acid type A receptor subunit alpha 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:57,057,417...57,240,808
Ensembl chr 7:57,057,420...57,159,807

G

gamma-aminobutyric acid type A receptor subunit beta 2

increases expression
multiple interactions

mercuric bromide results in increased expression of GABRB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:42,310,342...42,523,418
Ensembl chr11:42,310,584...42,519,855

G

GABRB3, gamma-aminobutyric acid type A receptor subunit beta 3

increases expression
multiple interactions

mercuric bromide results in increased expression of GABRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:57,240,266...57,478,550
Ensembl chr 7:57,069,440...57,478,550

G

gamma-aminobutyric acid type A receptor subunit pi

increases expression
multiple interactions

mercuric bromide results in increased expression of GABRP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA

PMID:26272509 PMID:27188386

NCBI chr11:33,500,781...33,528,978
Ensembl chr11:33,500,781...33,528,959

G

growth arrest and DNA-damage-inducible 45 alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of GADD45A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

growth arrest and DNA-damage-inducible 45 beta

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA

NCBI chr10:80,765,925...80,768,038
Ensembl chr10:80,765,907...80,768,038

G

galanin and GMAP prepropeptide

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GAL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA

PMID:26272509 PMID:27188386

NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544

G

polypeptide N-acetylgalactosaminyltransferase 10

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GALNT10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:57,536,268...57,678,327
Ensembl chr11:57,536,268...57,678,340

G

polypeptide N-acetylgalactosaminyltransferase 14

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GALNT14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:73,800,202...74,019,138
Ensembl chr17:73,800,223...74,017,448

G

polypeptide N-acetylgalactosaminyltransferase 3

increases expression
multiple interactions

mercuric bromide results in increased expression of GALNT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:65,913,110...65,955,217
Ensembl chr 2:65,913,110...65,955,338

G

galanin-like peptide

decreases expression

mercuric bromide results in decreased expression of GALP mRNA

NCBI chr 7:6,200,089...6,219,136
Ensembl chr 7:6,200,089...6,219,136

G

growth arrest specific 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:60,322,219...60,325,179
Ensembl chr13:60,322,219...60,325,179

G

growth arrest-specific 2 like 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GAS2L1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:5,004,131...5,015,351
Ensembl chr11:5,004,132...5,015,327

G

golgi associated kinase 1B

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GASK1B mRNA

NCBI chr 3:79,791,795...79,853,585
Ensembl chr 3:79,791,840...79,853,587

G

GATA binding protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of GATA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014

G

GATA binding protein 3

increases expression
multiple interactions

mercuric bromide results in increased expression of GATA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845

G

GATA binding protein 6

increases expression
multiple interactions

mercuric bromide results in increased expression of GATA6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:11,052,510...11,085,636
Ensembl chr18:11,052,064...11,085,635

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

mercuric bromide results in increased expression of GCLC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

increases expression
multiple interactions

mercuric bromide results in increased expression of GCLM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

glucosaminyl (N-acetyl) transferase 1, core 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GCNT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:17,303,505...17,350,208
Ensembl chr19:17,303,505...17,350,208

G

ganglioside-induced differentiation-associated protein 1-like 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA

NCBI chr 2:163,280,387...163,297,264
Ensembl chr 2:163,280,396...163,297,244

G

growth differentiation factor 15

increases expression
multiple interactions

mercuric bromide results in increased expression of GDF15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106

G

gap junction protein, beta 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA

NCBI chr14:57,336,059...57,342,159
Ensembl chr14:57,336,057...57,342,159

G

GLI pathogenesis related 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLIPR1 mRNA

NCBI chr10:111,821,353...111,838,539
Ensembl chr10:111,821,353...111,838,536

G

GLIS family zinc finger 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:28,236,251...28,657,684
Ensembl chr19:28,236,251...28,657,477

G

glutaredoxin 2

increases expression
multiple interactions

mercuric bromide results in increased expression of GLRX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:143,614,787...143,625,416
Ensembl chr 1:143,592,076...143,625,414

G

glutaminase

increases expression
multiple interactions

mercuric bromide results in increased expression of GLS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391

G

predicted gene 13889

decreases expression
multiple interactions

mercuric bromide results in decreased expression of C11ORF96 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C11ORF96 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:93,786,155...93,787,445
Ensembl chr 2:93,786,155...93,787,546

G

predicted gene 7694

decreases expression
multiple interactions

mercuric bromide results in decreased expression of C1ORF226 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:170,125,767...170,133,901
Ensembl chr 1:170,125,768...170,133,901

G

guanine nucleotide binding protein, alpha 14

increases expression
multiple interactions

mercuric bromide results in increased expression of GNA14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNA14 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:16,413,031...16,590,706
Ensembl chr19:16,413,126...16,588,184

G

GNAS complex locus

increases expression

mercuric bromide results in increased expression of GNAS mRNA

NCBI chr 2:174,126,113...174,188,537
Ensembl chr 2:174,126,113...174,188,537

G

GNAS antisense RNA 1

multiple interactions
decreases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA
mercuric bromide results in decreased expression of GNAS-AS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:174,123,030...174,137,229
Ensembl chr 2:174,123,024...174,137,229

G

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GNE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:44,034,075...44,084,177
Ensembl chr 4:44,034,075...44,084,177

G

guanine nucleotide binding protein (G protein), gamma 11

increases expression

mercuric bromide results in increased expression of GNG11 mRNA

NCBI chr 6:4,003,987...4,008,445
Ensembl chr 6:4,003,904...4,008,445

G

guanine nucleotide binding protein (G protein), gamma 8

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GNG8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:16,625,687...16,629,361
Ensembl chr 7:16,625,711...16,629,361

G

glycerol-3-phosphate acyltransferase 3

increases expression
multiple interactions

mercuric bromide results in increased expression of GPAT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:100,994,095...101,046,968
Ensembl chr 5:100,993,579...101,046,968

G

glycoprotein m6a

increases expression

mercuric bromide results in increased expression of GPM6A mRNA

NCBI chr 8:55,232,469...55,513,913
Ensembl chr 8:55,407,878...55,513,906

G

glycoprotein m6b

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GPM6B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA

PMID:26272509 PMID:27188386

NCBI chr X:165,021,911...165,172,028
Ensembl chr X:165,021,907...165,171,984

G

glycoprotein (transmembrane) nmb

increases expression
multiple interactions

mercuric bromide results in increased expression of GPNMB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:49,013,449...49,044,413
Ensembl chr 6:49,013,480...49,047,863

G

G protein-coupled receptor 153

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GPR153 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:152,358,563...152,369,798
Ensembl chr 4:152,358,689...152,369,794

G

G protein-coupled receptor 27

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GPR27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:99,669,328...99,672,027
Ensembl chr 6:99,669,640...99,672,027

G

G protein-coupled receptor 37

increases expression
multiple interactions

mercuric bromide results in increased expression of GPR37 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:25,668,522...25,689,979
Ensembl chr 6:25,665,877...25,690,728

G

G protein-coupled receptor 39

increases expression
multiple interactions

mercuric bromide results in increased expression of GPR39 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR39 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:125,604,725...125,804,132
Ensembl chr 1:125,604,732...125,801,599

G

G protein-coupled receptor 87

increases expression
multiple interactions

mercuric bromide results in increased expression of GPR87 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR87 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:59,086,325...59,102,583
Ensembl chr 3:59,086,344...59,102,525

G

G protein-coupled receptor, family C, group 5, member A

increases expression
multiple interactions

mercuric bromide results in increased expression of GPRC5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPRC5A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:135,042,660...135,061,707
Ensembl chr 6:135,042,649...135,061,707

G

glutathione peroxidase 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPX3 mRNA

NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203

G

GRAM domain containing 1C

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GRAMD1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA

PMID:26272509 PMID:27188386

NCBI chr16:43,800,713...43,883,757
Ensembl chr16:43,800,713...43,883,708

G

gremlin 1, DAN family BMP antagonist

increases expression
multiple interactions

mercuric bromide results in increased expression of GREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:113,579,020...113,588,993
Ensembl chr 2:113,576,509...113,588,991

G

grainyhead like transcription factor 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA

NCBI chr12:24,622,234...24,667,390
Ensembl chr12:24,622,282...24,667,390

G

grainyhead like transcription factor 2

increases expression
multiple interactions

mercuric bromide results in increased expression of GRHL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:37,233,065...37,363,813
Ensembl chr15:37,233,280...37,363,813

G

grainyhead like transcription factor 3

increases expression
multiple interactions

mercuric bromide results in increased expression of GRHL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:135,269,199...135,300,943
Ensembl chr 4:135,269,199...135,300,941

G

glutamate receptor, ionotropic, AMPA3 (alpha 3)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:40,489,351...40,767,478
Ensembl chr X:40,489,731...40,767,478

G

glutamate receptor, ionotropic, NMDA2A (epsilon 1)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GRIN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA

PMID:26272509 PMID:27188386

NCBI chr16:9,385,765...9,813,744
Ensembl chr16:9,385,762...9,813,424

G

glutathione reductase

increases expression
multiple interactions

mercuric bromide results in increased expression of GSR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione S-transferase, mu 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of GSTM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769

G

glutathione S-transferase, pi 1

increases expression
multiple interactions

mercuric bromide results in increased expression of GSTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

guanylate cyclase activator 1a (retina)

multiple interactions
decreases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA
mercuric bromide results in decreased expression of GUCA1A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:47,705,482...47,724,439
Ensembl chr17:47,705,483...47,711,509

G

GULP, engulfment adaptor PTB domain containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of GULP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GULP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:44,590,540...44,835,998
Ensembl chr 1:44,590,671...44,835,998

G

glucoside xylosyltransferase 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA

NCBI chr 6:100,681,638...100,787,738
Ensembl chr 6:100,681,695...100,787,874

G

H1.3 linker histone, cluster member

decreases expression

mercuric bromide results in decreased expression of H1-3 mRNA

NCBI chr13:23,739,206...23,739,981
Ensembl chr13:23,737,436...23,744,860

G

histocompatibility 2, class II, locus DMa

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMA mRNA

NCBI chr17:34,338,667...34,358,075
Ensembl chr17:34,338,515...34,358,075

G

histocompatibility 2, class II, locus Mb1

multiple interactions
decreases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA
mercuric bromide results in decreased expression of HLA-DMB mRNA

PMID:26272509 PMID:27188386

NCBI chr17:34,372,165...34,379,203
Ensembl chr17:34,372,046...34,379,204

G

histocompatibility 2, O region alpha locus

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HLA-DOA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DOA mRNA

PMID:26272509 PMID:27188386

NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208

G

H2B clustered histone 14

decreases expression
multiple interactions

mercuric bromide results in decreased expression of H2BC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:21,906,214...21,906,696
Ensembl chr13:21,906,214...21,906,737

G

3-hydroxyacyl-CoA dehydratase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of HACD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:14,031,642...14,060,846
Ensembl chr 2:13,855,093...14,060,847

G

heart and neural crest derivatives expressed 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA

NCBI chr11:57,719,539...57,722,973
Ensembl chr11:57,719,531...57,723,644

G

hyaluronan and proteoglycan link protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of HAPLN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:89,688,654...89,759,951
Ensembl chr13:89,687,915...89,759,771

G

high density lipoprotein (HDL) binding protein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HDLBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDLBP mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:93,333,662...93,406,639
Ensembl chr 1:93,333,662...93,406,537

G

homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA

NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005

G

hes family bHLH transcription factor 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HES5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:155,042,358...155,046,829
Ensembl chr 4:155,045,380...155,046,828

G

hexosaminidase A

increases expression
multiple interactions

mercuric bromide results in increased expression of HEXA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEXA mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:59,446,966...59,472,392
Ensembl chr 9:59,446,823...59,472,392

G

heparan-alpha-glucosaminide N-acetyltransferase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HGSNAT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:26,432,495...26,466,704
Ensembl chr 8:26,434,481...26,466,781

G

hypoxia inducible factor 3, alpha subunit

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA

NCBI chr 7:16,764,918...16,796,352
Ensembl chr 7:16,765,432...16,796,352

G

human immunodeficiency virus type I enhancer binding protein 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP1 mRNA

NCBI chr13:42,205,304...42,338,504
Ensembl chr13:42,205,497...42,346,013

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HMGCS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796

G

heme oxygenase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of HMOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

histamine N-methyltransferase

increases expression
multiple interactions

mercuric bromide results in increased expression of HNMT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:23,892,923...23,939,756
Ensembl chr 2:23,892,922...23,939,406

G

heterogeneous nuclear ribonucleoprotein R

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HNRNPR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:136,038,230...136,086,758
Ensembl chr 4:136,038,253...136,086,758

G

hydroxyprostaglandin dehydrogenase 15 (NAD)

increases expression
multiple interactions

mercuric bromide results in increased expression of HPGD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:56,747,587...56,774,081
Ensembl chr 8:56,747,620...56,774,078

G

histamine receptor H3

increases expression
multiple interactions

mercuric bromide results in increased expression of HRH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:179,741,258...179,746,264
Ensembl chr 2:179,741,258...179,746,281

G

harakiri, BCL2 interacting protein (contains only BH3 domain)

increases expression
multiple interactions

mercuric bromide results in increased expression of HRK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:118,307,829...118,327,543
Ensembl chr 5:118,302,713...118,327,543

G

heparan sulfate (glucosamine) 3-O-sulfotransferase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of HS3ST1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:39,771,278...39,802,791
Ensembl chr 5:39,771,278...39,912,818

G

heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HS3ST3A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:64,326,158...64,413,667
Ensembl chr11:64,326,158...64,413,667

G

heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:63,775,519...63,813,110
Ensembl chr11:63,776,618...63,813,116

G

hydroxysteroid 17-beta dehydrogenase 8

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HSD17B8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:34,245,007...34,247,029
Ensembl chr17:34,245,007...34,247,034

G

heat shock protein 4 like

increases expression
multiple interactions

mercuric bromide results in increased expression of HSPA4L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:40,698,664...40,750,538
Ensembl chr 3:40,699,814...40,750,538

G

heat shock protein 8

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA

NCBI chr 5:116,546,550...116,560,923
Ensembl chr 5:116,546,550...116,560,923

G

heat shock 105kDa/110kDa protein 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA

NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841

G

HIV-1 Tat interactive protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of HTATIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:49,408,761...49,423,748
Ensembl chr 7:49,408,863...49,423,723

G

HtrA serine peptidase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of HTRA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390

G

inhibitor of DNA binding 1, HLH protein

increases expression
multiple interactions

mercuric bromide results in increased expression of ID1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330

G

isocitrate dehydrogenase 3 (NAD+) alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of IDH3A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945

G

iduronate 2-sulfatase

increases expression
multiple interactions

mercuric bromide results in increased expression of IDS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA

PMID:26272509 PMID:27188386

NCBI chr X:69,386,675...69,429,437
Ensembl chr X:69,386,675...69,408,690

G

immediate early response 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

interferon activated gene 204

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA

NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509

G

interferon-related developmental regulator 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA

NCBI chr12:40,253,128...40,273,184
Ensembl chr12:40,251,566...40,298,503

G

intraflagellar transport 57

decreases expression
multiple interactions

mercuric bromide results in decreased expression of IFT57 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:49,519,657...49,585,489
Ensembl chr16:49,519,596...49,585,489

G

insulin-like growth factor binding protein 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of IGFBP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923

G

insulin-like growth factor binding protein 5

decreases expression

mercuric bromide results in decreased expression of IGFBP5 mRNA

NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043

G

insulin-like growth factor binding protein 6

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP6 mRNA

NCBI chr15:102,052,621...102,057,947
Ensembl chr15:102,052,797...102,057,946

G

insulin-like growth factor binding protein 7

increases expression
multiple interactions

mercuric bromide results in increased expression of IGFBP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:77,497,092...77,555,892
Ensembl chr 5:77,497,087...77,555,888

G

immunoglobulin superfamily, member 21

decreases expression
multiple interactions

mercuric bromide results in decreased expression of IGSF21 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:139,754,163...139,974,294
Ensembl chr 4:139,754,157...139,974,095

G

interleukin 13 receptor, alpha 1

increases expression
multiple interactions

mercuric bromide results in increased expression of IL13RA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:35,375,761...35,434,915
Ensembl chr X:35,375,763...35,434,912

G

interleukin 1 receptor accessory protein

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA

NCBI chr16:26,400,259...26,548,878
Ensembl chr16:26,400,454...26,548,867

G

interleukin 6

increases expression

mercuric bromide results in increased expression of IL6 mRNA

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 6 receptor, alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of IL6R mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

inverted formin, FH2 and WH2 domain containing

increases expression
multiple interactions

mercuric bromide results in increased expression of INF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:112,555,121...112,581,991
Ensembl chr12:112,555,218...112,581,991

G

inhibin beta-E

increases expression
multiple interactions

mercuric bromide results in increased expression of INHBE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA

PMID:26272509 PMID:27188386

NCBI chr10:127,185,271...127,187,717
Ensembl chr10:127,184,726...127,190,280

G

INO80 complex subunit D

decreases expression
multiple interactions

mercuric bromide results in decreased expression of INO80D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INO80D mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:63,086,960...63,153,693
Ensembl chr 1:62,997,577...63,153,849

G

inositol polyphosphate-5-phosphatase D

increases expression
multiple interactions

mercuric bromide results in increased expression of INPP5D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:87,548,034...87,648,232
Ensembl chr 1:87,548,034...87,648,229

G

insulin induced gene 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of INSIG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660

G

IQ motif containing E

decreases expression
multiple interactions

mercuric bromide results in decreased expression of IQCE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IQCE mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:140,648,308...140,688,158
Ensembl chr 5:140,647,582...140,688,133

G

insulin receptor substrate 1

increases expression
multiple interactions

mercuric bromide results in increased expression of IRS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137

G

ISL1 transcription factor, LIM/homeodomain

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA

NCBI chr13:116,434,806...116,446,224
Ensembl chr13:116,434,817...116,446,225

G

insulin related protein 2 (islet 2)

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA

NCBI chr 9:55,445,961...55,454,951
Ensembl chr 9:55,445,956...55,453,464

G

increased sodium tolerance 1 homolog (yeast)

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA

NCBI chr 8:110,397,953...110,419,929
Ensembl chr 8:110,397,957...110,419,892

G

integrin alpha 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ITGA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467

G

integrin alpha 8

increases expression
multiple interactions

mercuric bromide results in increased expression of ITGA8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:12,111,443...12,306,755
Ensembl chr 2:12,111,443...12,306,733

G

integrin beta 6

multiple interactions
increases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGB6 mRNA
mercuric bromide results in increased expression of ITGB6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:60,428,636...60,553,005
Ensembl chr 2:60,428,636...60,552,987

G

inter-alpha-trypsin inhibitor, heavy chain 5

increases expression
multiple interactions

mercuric bromide results in increased expression of ITIH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:10,158,354...10,261,340
Ensembl chr 2:10,158,382...10,261,340

G

integral membrane protein 2A

increases expression
multiple interactions

mercuric bromide results in increased expression of ITM2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA

PMID:26272509 PMID:27188386

NCBI chr X:106,440,801...106,446,966
Ensembl chr X:106,440,705...106,446,982

G

integral membrane protein 2B

increases expression
multiple interactions

mercuric bromide results in increased expression of ITM2B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2B mRNA

PMID:26272509 PMID:27188386

NCBI chr14:73,599,666...73,622,729
Ensembl chr14:73,599,666...73,622,729

G

inositol 1,4,5-triphosphate receptor 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ITPR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:146,009,797...146,403,757
Ensembl chr 6:146,009,797...146,403,721

G

junction adhesion molecule 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of JAM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:84,571,011...84,623,268
Ensembl chr16:84,571,011...84,622,816

G

JAZF zinc finger 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of JAZF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:52,745,050...53,045,613
Ensembl chr 6:52,745,782...53,045,616

G

junctophilin 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of JPH4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:55,344,283...55,354,392
Ensembl chr14:55,344,283...55,354,392

G

jun proto-oncogene

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

K(lysine) acetyltransferase 6A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KAT6A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:23,349,458...23,433,275
Ensembl chr 8:23,349,551...23,433,275

G

katanin p80 subunit B like 1

increases expression
multiple interactions

mercuric bromide results in increased expression of KATNBL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:112,209,556...112,244,582
Ensembl chr 2:112,209,556...112,244,585

G

potassium inwardly-rectifying channel, subfamily J, member 12

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KCNJ12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ12 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:60,912,970...60,964,095
Ensembl chr11:60,913,390...60,961,957

G

potassium channel, subfamily K, member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of KCNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:126,718,692...126,757,424
Ensembl chr 8:126,721,909...126,757,424

G

potassium channel, subfamily K, member 10

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KCNK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:98,395,691...98,544,472
Ensembl chr12:98,395,696...98,544,569

G

potassium voltage-gated channel, subfamily Q, member 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KCNQ2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNQ2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:180,717,372...180,777,368
Ensembl chr 2:180,717,372...180,777,093

G

potassium channel tetramerisation domain containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of KCTD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:15,101,742...15,284,503
Ensembl chr18:15,101,742...15,284,503

G

potassium channel tetramerisation domain containing 12

increases expression
multiple interactions

mercuric bromide results in increased expression of KCTD12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:103,214,017...103,220,073
Ensembl chr14:103,214,017...103,220,073

G

kelch-like ECH-associated protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of KEAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

kinesin family member 1A

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA

NCBI chr 1:92,943,180...93,029,760
Ensembl chr 1:92,943,186...93,029,673

G

kit ligand

increases expression
multiple interactions

mercuric bromide results in increased expression of KITLG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA

PMID:26272509 PMID:27188386

NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278

G

Kruppel-like transcription factor 11

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KLF11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF11 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:24,701,370...24,712,781
Ensembl chr12:24,701,273...24,712,788

G

Kruppel-like transcription factor 5

increases expression
multiple interactions

mercuric bromide results in increased expression of KLF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472

G

Kruppel-like transcription factor 6

increases expression
multiple interactions

mercuric bromide results in increased expression of KLF6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393

G

Kruppel-like transcription factor 9

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA

NCBI chr19:23,118,590...23,145,493
Ensembl chr19:23,118,590...23,145,498

G

kelch domain containing 8A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KLHDC8A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:132,226,352...132,236,216
Ensembl chr 1:132,226,364...132,235,095

G

kelch-like 21

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA

NCBI chr 4:152,093,348...152,102,134
Ensembl chr 4:152,093,260...152,102,137

G

kelch-like 4

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA

NCBI chr X:113,384,030...113,470,826
Ensembl chr X:113,384,030...113,470,526

G

kelch-like 5

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA

NCBI chr 5:65,264,894...65,325,490
Ensembl chr 5:65,264,882...65,325,531

G

kallikrein related-peptidase 8

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KLK8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:43,447,001...43,453,250
Ensembl chr 7:43,447,001...43,453,250

G

kinase non-catalytic C-lobe domain (KIND) containing 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KNDC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNDC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:139,474,612...139,521,453
Ensembl chr 7:139,474,612...139,521,450

G

Kirsten rat sarcoma viral oncogene homolog

decreases expression
multiple interactions

mercuric bromide results in decreased expression of KRAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965

G

keratin 18

increases expression
multiple interactions

mercuric bromide results in increased expression of KRT18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462

G

keratin 8

increases expression
multiple interactions

mercuric bromide results in increased expression of KRT8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:101,905,146...101,912,777
Ensembl chr15:101,905,133...101,912,917

G

laccase domain containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of LACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:77,261,640...77,274,344
Ensembl chr14:77,261,640...77,274,344

G

lactamase, beta

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA

NCBI chr 9:66,862,668...66,882,706
Ensembl chr 9:66,862,670...66,882,766

G

laminin, gamma 2

increases expression
multiple interactions

mercuric bromide results in increased expression of LAMC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193

G

lysosomal-associated membrane protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of LAMP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:37,488,524...37,545,337
Ensembl chr X:37,490,234...37,545,331

G

layilin

increases expression
multiple interactions

mercuric bromide results in increased expression of LAYN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:50,966,323...50,988,501
Ensembl chr 9:50,965,940...50,988,394

G

lectin, galactose binding, soluble 3

increases expression
multiple interactions

mercuric bromide results in increased expression of LGALS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:47,611,317...47,623,624
Ensembl chr14:47,605,208...47,623,617

G

lectin, galactose binding, soluble 8

increases expression
multiple interactions

mercuric bromide results in increased expression of LGALS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS8 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:12,454,283...12,479,857
Ensembl chr13:12,454,296...12,479,825

G

lipoma HMGIC fusion partner-like protein 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LHFPL4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHFPL4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:113,145,048...113,172,345
Ensembl chr 6:113,145,051...113,172,345

G

LHFPL tetraspan subfamily member 6

increases expression
multiple interactions

mercuric bromide results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:52,948,968...53,169,100
Ensembl chr 3:52,948,949...53,169,100

G

LIM homeobox protein 2

decreases expression

mercuric bromide results in decreased expression of LHX2 mRNA

NCBI chr 2:38,229,282...38,259,747
Ensembl chr 2:38,229,293...38,259,745

G

LIM homeobox protein 4

increases expression

mercuric bromide results in increased expression of LHX4 mRNA

NCBI chr 1:155,573,777...155,627,481
Ensembl chr 1:155,573,777...155,627,430

G

LIM homeobox protein 8

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA

NCBI chr 3:154,011,925...154,036,190
Ensembl chr 3:154,011,931...154,036,296

G

LIF receptor alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of LIFR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA

PMID:26272509 PMID:27188386

NCBI chr15:7,120,091...7,226,970
Ensembl chr15:7,120,095...7,226,970

G

lens intrinsic membrane protein 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA

NCBI chr 7:43,079,523...43,085,420
Ensembl chr 7:43,079,512...43,085,420

G

LIM and calponin homology domains 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMCH1 mRNA

NCBI chr 5:66,903,232...67,214,502
Ensembl chr 5:66,903,170...67,214,501

G

limb and CNS expressed 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LIX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:17,622,948...17,679,649
Ensembl chr17:17,622,934...17,679,649

G

lectin, mannose-binding, 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:66,113,810...66,135,706
Ensembl chr18:66,113,809...66,155,651

G

lamin A

increases expression
multiple interactions

mercuric bromide results in increased expression of LMNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMNA mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:88,388,455...88,413,842
Ensembl chr 3:88,387,454...88,417,263

G

LIM domain only 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LMO1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:108,737,776...108,774,356
Ensembl chr 7:108,737,779...108,774,414

G

LIM domain only 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LMO3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:138,339,916...138,559,204
Ensembl chr 6:138,339,916...138,558,966

G

LIM domain only 7

increases expression
multiple interactions

mercuric bromide results in increased expression of LMO7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:101,967,353...102,172,144
Ensembl chr14:101,967,386...102,172,146

G

long non-protein coding RNA, Trp53 induced transcript

increases expression
multiple interactions

mercuric bromide results in increased expression of LINC-PINT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC-PINT mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:31,070,498...31,195,409
Ensembl chr 6:31,059,500...31,197,423

G

ligand of numb-protein X 1

increases expression
multiple interactions

mercuric bromide results in increased expression of LNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:74,753,108...74,865,203
Ensembl chr 5:74,753,108...74,863,573

G

lysophosphatidic acid receptor 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LPAR3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:145,926,716...145,991,969
Ensembl chr 3:145,926,718...145,991,941

G

lysophosphatidic acid receptor 6

increases expression

mercuric bromide results in increased expression of LPAR6 mRNA

NCBI chr14:73,475,331...73,477,798
Ensembl chr14:73,475,335...73,480,734

G

low-density lipoprotein receptor-related protein 10

increases expression
multiple interactions

mercuric bromide results in increased expression of LRP10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:54,701,260...54,707,749
Ensembl chr14:54,701,594...54,708,954

G

leucine rich repeat containing 34

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LRRC34 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:30,678,416...30,701,967
Ensembl chr 3:30,678,416...30,702,018

G

leucine rich repeat containing 3B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LRRC3B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA

PMID:26272509 PMID:27188386

NCBI chr14:7,030,776...7,112,248
Ensembl chr14:7,030,776...7,112,248

G

leucine rich repeat neuronal 4

increases expression

mercuric bromide results in increased expression of LRRN4 mRNA

NCBI chr 2:132,710,436...132,735,930
Ensembl chr 2:132,710,225...132,722,811

G

limbic system-associated membrane protein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of LSAMP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA

PMID:26272509 PMID:27188386

NCBI chr16:39,804,674...42,002,042
Ensembl chr16:39,804,723...42,002,042

G

lymphocyte antigen 6 family member K

increases expression
multiple interactions

mercuric bromide results in increased expression of LY6K mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY6K mRNA

PMID:26272509 PMID:27188386

NCBI chr15:74,668,723...74,671,817
Ensembl chr15:74,668,723...74,671,835

G

lymphatic vessel endothelial hyaluronan receptor 1

increases expression
multiple interactions

mercuric bromide results in increased expression of LYVE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYVE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:110,449,814...110,462,160
Ensembl chr 7:110,449,814...110,462,446

G

leucine zipper, putative tumor suppressor 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA

NCBI chr 8:69,585,311...69,636,901
Ensembl chr 8:69,585,321...69,636,877

G

mab-21-like 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:86,453,357...86,455,590
Ensembl chr 3:86,452,888...86,455,590

G

metastasis associated in colon cancer 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:119,354,133...119,430,669
Ensembl chr12:119,278,005...119,433,722

G

macroH2A.1 histone

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:56,221,435...56,283,439
Ensembl chr13:56,221,432...56,284,174

G

MAF bZIP transcription factor B

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA

NCBI chr 2:160,205,597...160,208,985
Ensembl chr 2:160,205,623...160,208,985

G

v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian)

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA

NCBI chr15:79,230,813...79,243,278
Ensembl chr15:79,230,821...79,243,276

G

v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian)

increases expression
multiple interactions

mercuric bromide results in increased expression of MAFG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA

PMID:26272509 PMID:27188386

NCBI chr11:120,515,943...120,525,771
Ensembl chr11:120,515,943...120,524,426

G

mal, T cell differentiation protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of MAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:54,434,762...54,466,242
Ensembl chr15:54,434,588...54,466,243

G

mannosidase 1, alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:53,780,881...53,952,712
Ensembl chr10:53,780,881...53,952,705

G

mannosidase, alpha, class 1C, member 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MAN1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:134,289,001...134,432,987
Ensembl chr 4:134,289,001...134,431,601

G

microtubule-associated protein 1 A

increases expression
multiple interactions

mercuric bromide results in increased expression of MAP1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:121,119,608...121,141,313
Ensembl chr 2:121,120,081...121,141,313

G

mitogen-activated protein kinase kinase 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MAP2K6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348

G

mitogen-activated protein kinase kinase kinase 14

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA

NCBI chr11:103,110,590...103,158,227
Ensembl chr11:103,110,588...103,158,298

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA

NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499

G

microtubule-associated protein 4

increases expression
multiple interactions

mercuric bromide results in increased expression of MAP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:109,758,909...109,913,018
Ensembl chr 9:109,760,528...109,913,023

G

mitogen-activated protein kinase kinase kinase kinase 4

increases expression

mercuric bromide results in increased expression of MAP4K4 mRNA

NCBI chr 1:39,939,806...40,065,470
Ensembl chr 1:39,940,073...40,065,470

G

microtubule-associated protein 6

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA

NCBI chr 7:98,916,270...98,986,344
Ensembl chr 7:98,916,654...98,986,344

G

microtubule-associated protein 7

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MAP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:20,024,666...20,157,336
Ensembl chr10:20,024,217...20,157,336

G

mitogen-activated protein kinase 10

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:103,056,413...103,359,200
Ensembl chr 5:103,055,814...103,359,200

G

MARVEL (membrane-associating) domain containing 3

increases expression
multiple interactions

mercuric bromide results in increased expression of MARVELD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:110,674,541...110,688,837
Ensembl chr 8:110,674,546...110,688,835

G

microtubule associated serine/threonine kinase family member 4

increases expression
multiple interactions

mercuric bromide results in increased expression of MAST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAST4 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:102,868,996...103,471,607
Ensembl chr13:102,868,994...103,471,005

G

methyl-CpG binding domain protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of MBD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:70,701,298...70,761,769
Ensembl chr18:70,701,260...70,759,202

G

muscleblind like splicing factor 3

increases expression
multiple interactions

mercuric bromide results in increased expression of MBNL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:50,202,371...50,294,867
Ensembl chr X:50,206,146...50,295,409

G

membrane bound O-acyltransferase domain containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MBOAT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:30,320,499...30,430,677
Ensembl chr13:30,320,472...30,430,700

G

mutated in colorectal cancers

increases expression
multiple interactions

mercuric bromide results in increased expression of MCC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:44,558,127...44,945,573
Ensembl chr18:44,558,127...44,945,249

G

minichromosome maintenance complex component 7

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MCM7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684

G

mucolipin 3

increases expression
multiple interactions

mercuric bromide results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:145,799,032...145,847,563
Ensembl chr 3:145,823,205...145,847,561

G

multiple C2 domains, transmembrane 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MCTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:76,530,481...77,181,403
Ensembl chr13:76,532,259...77,179,929

G

transformed mouse 3T3 cell double minute 2

increases expression
multiple interactions

mercuric bromide results in increased expression of MDM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

malic enzyme 1, NADP(+)-dependent, cytosolic

increases expression
multiple interactions

mercuric bromide results in increased expression of ME1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

multiple EGF-like-domains 10

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MEGF10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEGF10 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:57,266,162...57,430,539
Ensembl chr18:57,266,162...57,430,539

G

meiosis specific with OB domains

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MEIOB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA

PMID:26272509 PMID:27188386

NCBI chr17:25,023,275...25,058,762
Ensembl chr17:25,023,263...25,058,762

G

melanotransferrin

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MELTF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MELTF mRNA

PMID:26272509 PMID:27188386

NCBI chr16:31,697,449...31,717,838
Ensembl chr16:31,697,628...31,717,838

G

mesenchyme homeobox 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MEOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:101,768,336...101,785,309
Ensembl chr11:101,768,336...101,785,200

G

microfibrillar-associated protein 3-like

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:61,085,859...61,129,765
Ensembl chr 8:61,085,861...61,129,763

G

microfibrillar associated protein 5

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mRNA

NCBI chr 6:122,490,543...122,506,249
Ensembl chr 6:122,482,804...122,506,249

G

MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MFNG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA

PMID:26272509 PMID:27188386

NCBI chr15:78,640,082...78,657,678
Ensembl chr15:78,640,082...78,657,675

G

mitochondria localized glutamic acid rich protein

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mRNA

NCBI chr 3:51,295,833...51,303,968
Ensembl chr 3:51,295,833...51,304,159

G

MIF4G domain containing

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MIF4GD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA

PMID:26272509 PMID:27188386

NCBI chr11:115,498,744...115,503,795
Ensembl chr11:115,498,744...115,503,795

G

Mir22 host gene (non-protein coding)

increases expression
multiple interactions

mercuric bromide results in increased expression of MIR22HG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA

PMID:26272509 PMID:27188386

NCBI chr11:75,352,365...75,357,516
Ensembl chr11:75,352,365...75,357,502

G

melanogenesis associated transcription factor

increases expression
multiple interactions

mercuric bromide results in increased expression of MITF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:97,783,966...97,998,321
Ensembl chr 6:97,784,013...97,998,310

G

methylmalonic aciduria (cobalamin deficiency) cblB type homolog (human)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MMAB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:114,569,095...114,582,134
Ensembl chr 5:114,569,095...114,582,121

G

matrix metallopeptidase 14 (membrane-inserted)

increases expression
multiple interactions

mercuric bromide results in increased expression of MMP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821

G

matrix metallopeptidase 16

decreases expression

mercuric bromide results in decreased expression of MMP16 mRNA

NCBI chr 4:17,853,072...18,117,479
Ensembl chr 4:17,852,893...18,119,145

G

motor neuron and pancreas homeobox 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:29,678,821...29,683,468
Ensembl chr 5:29,678,032...29,683,468

G

myelin protein zero-like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of MPZL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:44,951,595...44,965,341
Ensembl chr 9:44,951,097...44,965,313

G

MAS-related GPR, member F

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA

NCBI chr 7:144,854,646...144,863,294
Ensembl chr 7:144,854,565...144,863,294

G

mitochondrial ribosomal protein L4

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRPL4 mRNA

NCBI chr 9:20,907,040...20,920,135
Ensembl chr 9:20,914,034...20,920,135

G

methionine sulfoxide reductase B3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:120,617,005...120,735,132
Ensembl chr10:120,617,001...120,735,006

G

msh homeobox 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MSX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:37,977,835...37,981,929
Ensembl chr 5:37,977,829...37,981,927

G

msh homeobox 2

increases expression
multiple interactions

mercuric bromide results in increased expression of MSX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:53,620,917...53,626,816
Ensembl chr13:53,620,920...53,627,110

G

metallothionein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of MT1X mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of MT2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

MTSS I-BAR domain containing 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MTSS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:58,813,083...58,955,805
Ensembl chr15:58,813,083...58,953,854

G

mucin 15

increases expression
multiple interactions

mercuric bromide results in increased expression of MUC15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:110,551,839...110,569,882
Ensembl chr 2:110,551,685...110,569,872

G

v-myc avian myelocytomatosis viral oncogene lung carcinoma derived

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MYCL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:122,889,414...122,896,278
Ensembl chr 4:122,889,445...122,896,278

G

myc target 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA

NCBI chr10:5,543,728...5,556,789
Ensembl chr10:5,543,775...5,556,904

G

myosin, light polypeptide kinase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of MYLK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA

PMID:26272509 PMID:27188386

NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790

G

myosin X

increases expression
multiple interactions

mercuric bromide results in increased expression of MYO10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:25,622,636...25,813,759
Ensembl chr15:25,622,611...25,813,759

G

myosin ID

increases expression
multiple interactions

mercuric bromide results in increased expression of MYO1D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA

PMID:26272509 PMID:27188386

NCBI chr11:80,372,945...80,670,881
Ensembl chr11:80,372,952...80,670,851

G

myoferlin

increases expression
multiple interactions

mercuric bromide results in increased expression of MYOF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA

PMID:26272509 PMID:27188386

NCBI chr19:37,887,484...38,032,025
Ensembl chr19:37,887,484...38,032,025

G

NEDD4 binding protein 2-like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of N4BP2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:150,515,310...150,589,213
Ensembl chr 5:150,531,472...150,589,648

G

nucleic acid binding protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of NABP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:51,504,127...51,517,634
Ensembl chr 1:51,505,021...51,517,584

G

N-acetyl transferase 1

increases expression

mercuric bromide results in increased expression of NAT1 mRNA

NCBI chr 8:67,943,620...67,945,183
Ensembl chr 8:67,933,573...67,944,756

G

neuron navigator 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:135,362,318...135,616,082
Ensembl chr 1:135,362,318...135,615,843

G

neurocalcin delta

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NCALD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA

PMID:26272509 PMID:27188386

NCBI chr15:37,366,419...37,792,816
Ensembl chr15:37,366,419...37,792,814

G

neural cell adhesion molecule 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NCAM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:49,413,434...49,710,909
Ensembl chr 9:49,413,436...49,710,225

G

neurocan

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NCAN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:70,545,735...70,573,494
Ensembl chr 8:70,545,735...70,573,523

G

nuclear receptor coactivator 7

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NCOA7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:30,521,578...30,683,401
Ensembl chr10:30,504,995...30,679,322

G

Nedd4 family interacting protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of NDFIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDFIP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:105,495,975...105,546,732
Ensembl chr14:105,496,008...105,546,732

G

Norrie disease (pseudoglioma) (human)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NDP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA

PMID:26272509 PMID:27188386

NCBI chr X:16,751,760...16,778,013
Ensembl chr X:16,751,760...16,778,013

G

N-deacetylase/N-sulfotransferase (heparin glucosaminyl) 4

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDST4 mRNA

NCBI chr 3:125,197,678...125,522,550
Ensembl chr 3:125,197,725...125,522,548

G

NADH:ubiquinone oxidoreductase subunit B1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:101,934,355...101,941,997
Ensembl chr12:101,934,349...101,943,327

G

nuclear paraspeckle assembly transcript 1 (non-protein coding)

increases expression
multiple interactions

mercuric bromide results in increased expression of NEAT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:5,874,736...5,895,508
Ensembl chr19:5,874,736...5,895,898

G

nectin cell adhesion molecule 4

increases expression
multiple interactions

mercuric bromide results in increased expression of NECTIN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:171,197,741...171,215,855
Ensembl chr 1:171,197,667...171,216,166

G

neurofilament, heavy polypeptide

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NEFH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEFH mRNA

PMID:26272509 PMID:27188386

NCBI chr11:4,888,754...4,898,064
Ensembl chr11:4,888,754...4,898,064

G

neurofilament, light polypeptide

increases expression
multiple interactions

mercuric bromide results in increased expression of NEFL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA

PMID:26272509 PMID:27188386

NCBI chr14:68,321,312...68,326,544
Ensembl chr14:68,321,312...68,326,544

G

neurofilament, medium polypeptide

increases expression
multiple interactions

mercuric bromide results in increased expression of NEFM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA

PMID:26272509 PMID:27188386

NCBI chr14:68,356,994...68,362,453
Ensembl chr14:68,320,039...68,362,295

G

nei like 2 (E. coli)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NEIL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEIL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:63,419,888...63,431,604
Ensembl chr14:63,419,892...63,431,305

G

neurite extension and migration factor

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NEXMIF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA

PMID:26272509 PMID:27188386

NCBI chr X:103,120,367...103,245,403
Ensembl chr X:103,121,040...103,244,791

G

neurofibromin 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:79,223,541...79,472,435
Ensembl chr11:79,230,519...79,472,438

G

neurofascin

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NFASC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:132,492,428...132,669,567
Ensembl chr 1:132,492,428...132,669,535

G

nuclear factor, erythroid derived 2, like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of NFE2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor I/B

increases expression
multiple interactions

mercuric bromide results in increased expression of NFIB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:82,208,410...82,424,988
Ensembl chr 4:82,208,410...82,623,987

G

nescient helix loop helix 2

increases expression
multiple interactions

mercuric bromide results in increased expression of NHLH2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:101,917,425...101,922,808
Ensembl chr 3:101,917,392...101,922,808

G

NHS actin remodeling regulator

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NHS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA

PMID:26272509 PMID:27188386

NCBI chr X:160,616,286...160,942,437
Ensembl chr X:160,616,292...160,942,726

G

niban apoptosis regulator 1

increases expression
multiple interactions

mercuric bromide results in increased expression of NIBAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIBAN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:151,447,215...151,597,690
Ensembl chr 1:151,446,937...151,597,690

G

NIPA-like domain containing 2

increases expression
multiple interactions

mercuric bromide results in increased expression of NIPAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:34,572,942...34,679,739
Ensembl chr15:34,572,945...34,679,358

G

Na+/K+ transporting ATPase interacting 3

multiple interactions
decreases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
mercuric bromide results in decreased expression of NKAIN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:20,111,029...20,779,990
Ensembl chr 4:20,118,874...20,778,866

G

neurolysin (metallopeptidase M3 family)

increases expression
multiple interactions

mercuric bromide results in increased expression of NLN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA

PMID:26272509 PMID:27188386

NCBI chr13:104,159,558...104,246,170
Ensembl chr13:104,159,565...104,246,122

G

NLR family member X1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLRX1 mRNA

NCBI chr 9:44,164,010...44,179,896
Ensembl chr 9:44,164,014...44,179,896

G

NME/NM23 family member 8

increases expression
multiple interactions

mercuric bromide results in increased expression of NME8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:19,829,248...19,881,996
Ensembl chr13:19,829,248...19,881,964

G

nicotinamide riboside kinase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of NMRK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:18,609,380...18,629,555
Ensembl chr19:18,609,314...18,629,792

G

nocturnin

increases expression
multiple interactions

mercuric bromide results in increased expression of NOCT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:51,131,868...51,159,075
Ensembl chr 3:51,131,868...51,159,065

G

noggin

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP2B1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C11ORF96 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP263 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP96 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIMAP1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3P2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUTALP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DICER1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HCG11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDLBP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DOA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INO80D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IQCE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ12 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNQ2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNDC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHFPL4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00648 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01138 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEGF10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MELTF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR210HG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEFH mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEIL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLRX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPHP4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPRL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPTX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLFM3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPLN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAXIP1-DT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH18 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX13 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGM5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIERCE2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3R5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIP4K2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKNOX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU4F1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPFIA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPIL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R16A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R17 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRIMA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKCB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRORSD1P mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PSMB8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTP4A3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTX3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PYGM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAI2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBP7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REEP6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REPS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RET mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFLNB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIPPLY3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF125 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF130 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF32-DT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSKR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPH9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RUNDC3B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMD13 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEC24B-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOW mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEZ6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKIDA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC18A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC1A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A21-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A15 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMKR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNAP91 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOBP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPON1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SQLE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GAL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SULF1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNGR3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAPT1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCEAL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEKT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TIGD7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TINCR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM132D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM132E mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM150C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM231 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNFRSF19 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOB1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRAPPC6A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRMT1L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSFM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TWIST2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TYSND1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2QL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE3D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ULK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UPK1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VASH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VCAM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VWF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WASF3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of XPNPEP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB24 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF207 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF493 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF503-AS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF529 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF674-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF717 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS12 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH3B2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALPK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD33B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGDIB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCC3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP10D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V1C1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDNF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1ORF210 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH13 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP4C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL12A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL3A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREG1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSV mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DQX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTNA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUBR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERICH5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVMER61-1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM169A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLI1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GASK1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCNA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLIPR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNA14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR39 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR87 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPRC5A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPX3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GULP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEXA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGB6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMCH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC-PINT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01088 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01128 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01405 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMNA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY6K mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYVE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAST4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBD2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRPL4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1E mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1F mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1G mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1H mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1HL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDFIP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDST4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIBAN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPPB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR3C1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NT5E mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NTS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NXPE3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ONECUT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAK6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALLD mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAPPA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAWR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH17 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELO mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PERP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PI15 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMAIP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLH mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POSTN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1H mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PROSER2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTGER4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PVT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM20 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RETREG1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REV3L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPOR2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNFT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS27L mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAMD4A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAR1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SBF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCIN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SESN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SESN2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFXN5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH2D4A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHTN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIPA1L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC10A4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC22A15 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC44A3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN12 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPANXC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPRY4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPTLC3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQSTM1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRXN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST8SIA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STK17A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STS mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STX3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYBU mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNJ2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TEX19 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFE3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD7A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THUMPD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TJP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TM4SF18 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM37 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM40 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM63A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS13 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMTC3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFAIP6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRBC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIB3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC39C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TXNRD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UCHL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNKL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEGFA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC21P mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWTR1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XAGE2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YARS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZDHHC13 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZMAT3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA

NCBI chr11:89,191,464...89,193,385
Ensembl chr11:89,191,464...89,193,158

G

nucleolar protein 3 (apoptosis repressor with CARD domain)

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOL3 mRNA

NCBI chr 8:106,002,777...106,008,571
Ensembl chr 8:106,002,772...106,008,571

G

nitric oxide synthase 2, inducible

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NOS2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nephronophthisis 4 (juvenile) homolog (human)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NPHP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPHP4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:152,561,163...152,647,641
Ensembl chr 4:152,561,163...152,647,640

G

nephronectin

increases expression
multiple interactions

mercuric bromide results in increased expression of NPNT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPNT mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:132,587,506...132,656,052
Ensembl chr 3:132,587,506...132,656,052

G

natriuretic peptide type B

increases expression
multiple interactions

mercuric bromide results in increased expression of NPPB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPPB mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

nitrogen permease regulator-like 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NPRL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPRL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:32,181,963...32,217,707
Ensembl chr11:32,175,628...32,217,707

G

neuronal pentraxin 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPTX1 mRNA

NCBI chr11:119,429,545...119,438,646
Ensembl chr11:119,429,545...119,438,579

G

neuropeptide Y

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA

NCBI chr 6:49,799,690...49,806,487
Ensembl chr 6:49,799,690...49,806,487

G

neuropeptide Y receptor Y2

decreases expression

mercuric bromide results in decreased expression of NPY2R mRNA

NCBI chr 3:82,445,688...82,455,404
Ensembl chr 3:82,445,690...82,455,391

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

mercuric bromide results in increased expression of NQO1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 2, group F, member 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NR2F1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:78,337,090...78,346,954
Ensembl chr13:78,337,092...78,347,876

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA

NCBI chr 7:70,001,694...70,016,494
Ensembl chr 7:70,001,692...70,016,483

G

nuclear receptor subfamily 3, group C, member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of NR3C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR3C1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

nuclear receptor interacting protein 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NRIP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:109,357,263...109,380,752
Ensembl chr 7:109,357,262...109,381,232

G

Nik related kinase

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRK mRNA

NCBI chr X:137,814,980...137,911,281
Ensembl chr X:137,815,179...137,911,281

G

neuropilin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of NRP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:129,085,553...129,231,957
Ensembl chr 8:129,085,085...129,229,844

G

neurexin III

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NRXN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:88,689,454...90,301,709
Ensembl chr12:88,689,646...90,301,709

G

NSL1, MIS12 kinetochore complex component

decreases expression
multiple interactions

mercuric bromide results in decreased expression of NSL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:190,794,710...190,816,755
Ensembl chr 1:190,795,209...190,818,671

G

5' nucleotidase, ecto

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NT5E mRNA

NCBI chr 9:88,209,662...88,254,142
Ensembl chr 9:88,209,250...88,254,145

G

netrin 4

decreases expression

mercuric bromide results in decreased expression of NTN4 mRNA

NCBI chr10:93,476,911...93,581,834
Ensembl chr10:93,476,543...93,583,069

G

neurotensin

increases expression
multiple interactions

mercuric bromide results in increased expression of NTS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NTS mRNA

PMID:26272509 PMID:27188386

NCBI chr10:102,317,617...102,326,294
Ensembl chr10:102,317,617...102,326,347

G

neurexophilin and PC-esterase domain family, member 3

increases expression
multiple interactions

mercuric bromide results in increased expression of NXPE3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NXPE3 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:55,660,316...55,717,467
Ensembl chr16:55,660,316...55,715,648

G

olfactomedin 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLFM3 mRNA

NCBI chr 3:114,697,727...114,919,413
Ensembl chr 3:114,697,727...114,919,371

G

olfactomedin-like 1

increases expression
multiple interactions

mercuric bromide results in increased expression of OLFML1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:107,166,640...107,190,572
Ensembl chr 7:107,166,653...107,190,301

G

one cut domain, family member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of ONECUT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ONECUT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:64,473,098...64,531,559
Ensembl chr18:64,473,091...64,534,058

G

5-oxoprolinase (ATP-hydrolysing)

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA

NCBI chr15:76,180,803...76,215,381
Ensembl chr15:76,180,801...76,212,215

G

oxysterol binding protein-like 3

increases expression
multiple interactions

mercuric bromide results in increased expression of OSBPL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OSBPL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:50,270,307...50,433,334
Ensembl chr 6:50,270,310...50,433,181

G

oxysterol binding protein-like 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of OSBPL6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSBPL6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:76,236,848...76,430,991
Ensembl chr 2:76,236,852...76,430,991

G

ovo like zinc finger 1

increases expression
multiple interactions

mercuric bromide results in increased expression of OVOL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:5,599,165...5,610,603
Ensembl chr19:5,599,164...5,610,674

G

ovo like zinc finger 2

increases expression
multiple interactions

mercuric bromide results in increased expression of OVOL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:144,147,095...144,174,000
Ensembl chr 2:144,147,095...144,174,066

G

p21 (RAC1) activated kinase 6

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAK6 mRNA

NCBI chr 2:118,493,531...118,528,501
Ensembl chr 2:118,493,784...118,528,501

G

palladin, cytoskeletal associated protein

increases expression
multiple interactions

mercuric bromide results in increased expression of PALLD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALLD mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:61,964,465...62,355,741
Ensembl chr 8:61,964,467...62,355,724

G

peptidase domain containing associated with muscle regeneration 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PAMR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAMR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:102,380,325...102,473,386
Ensembl chr 2:102,380,357...102,473,386

G

papilin, proteoglycan-like sulfated glycoprotein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PAPLN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPLN mRNA

PMID:26272509 PMID:27188386

NCBI chr12:83,809,769...83,841,914
Ensembl chr12:83,810,408...83,839,156

G

pregnancy-associated plasma protein A

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAPPA mRNA

NCBI chr 4:65,041,993...65,276,776
Ensembl chr 4:65,042,411...65,275,746

G

PATJ, crumbs cell polarity complex component

increases expression
multiple interactions

mercuric bromide results in increased expression of PATJ mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PATJ mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:98,283,803...98,607,840
Ensembl chr 4:98,284,022...98,607,840

G

PRKC, apoptosis, WT1, regulator

increases expression
multiple interactions

mercuric bromide results in increased expression of PAWR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAWR mRNA

PMID:26272509 PMID:27188386

NCBI chr10:108,168,050...108,250,708
Ensembl chr10:108,167,982...108,250,101

G

paired box 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PAX6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAX6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:105,499,241...105,528,755
Ensembl chr 2:105,499,245...105,527,709

G

paired box 7

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA

NCBI chr 4:139,464,357...139,560,841
Ensembl chr 4:139,464,373...139,560,839

G

protocadherin 10

increases expression
multiple interactions

mercuric bromide results in increased expression of PCDH10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:45,332,833...45,389,014
Ensembl chr 3:45,332,833...45,390,058

G

protocadherin 17

increases expression
multiple interactions

mercuric bromide results in increased expression of PCDH17 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH17 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:84,680,626...84,775,005
Ensembl chr14:84,681,003...84,776,442

G

protocadherin 18

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PCDH18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:49,697,745...49,711,723
Ensembl chr 3:49,697,745...49,711,774

G

protocadherin 20

increases expression
multiple interactions

mercuric bromide results in increased expression of PCDH20 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH20 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:88,702,183...88,708,832
Ensembl chr14:88,702,179...88,708,832

G

protocadherin 8

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH8 mRNA

NCBI chr14:80,004,224...80,008,752
Ensembl chr14:80,004,215...80,008,752

G

protocadherin 9

increases expression

mercuric bromide results in increased expression of PCDH9 mRNA

NCBI chr14:93,251,136...94,132,619
Ensembl chr14:93,250,846...94,128,115

G

proprotein convertase subtilisin/kexin type 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PCSK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:75,237,407...75,282,980
Ensembl chr13:75,237,945...75,282,980

G

proprotein convertase subtilisin/kexin type 9

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PCSK9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:106,299,531...106,321,522
Ensembl chr 4:106,299,526...106,321,526

G

phosphodiesterase 10A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PDE10A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:8,742,719...9,205,480
Ensembl chr17:8,744,204...9,205,480

G

phosphodiesterase 3A, cGMP inhibited

increases expression
multiple interactions

mercuric bromide results in increased expression of PDE3A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE3A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:141,194,995...141,452,588
Ensembl chr 6:141,194,995...141,453,174

G

phosphodiesterase 4B, cAMP specific

increases expression

mercuric bromide results in increased expression of PDE4B mRNA

NCBI chr 4:101,944,529...102,464,459
Ensembl chr 4:101,944,740...102,464,456

G

phosphodiesterase 4D, cAMP specific

increases expression
multiple interactions

mercuric bromide results in increased expression of PDE4D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA

PMID:26272509 PMID:27188386

NCBI chr13:108,790,711...110,092,503
Ensembl chr13:108,586,482...110,089,995

G

platelet derived growth factor, B polypeptide

increases expression
multiple interactions

mercuric bromide results in increased expression of PDGFB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFB mRNA

PMID:26272509 PMID:27188386

NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178

G

platelet-derived growth factor, C polypeptide

increases expression
multiple interactions

mercuric bromide results in increased expression of PDGFC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFC mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:80,943,723...81,121,347
Ensembl chr 3:80,943,723...81,121,347

G

pyruvate dehydrogenase kinase, isoenzyme 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PDK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202

G

PDZ and LIM domain 1 (elfin)

increases expression
multiple interactions

mercuric bromide results in increased expression of PDLIM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:40,210,683...40,260,060
Ensembl chr19:40,209,617...40,260,286

G

podoplanin

increases expression
multiple interactions

mercuric bromide results in increased expression of PDPN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:142,993,979...143,026,134
Ensembl chr 4:142,994,001...143,026,134

G

pelota mRNA surveillance and ribosome rescue factor

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELO mRNA

NCBI chr13:115,224,891...115,226,694
Ensembl chr13:115,224,891...115,226,722

G

PERP, TP53 apoptosis effector

increases expression
multiple interactions

mercuric bromide results in increased expression of PERP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PERP mRNA

PMID:26272509 PMID:27188386

NCBI chr10:18,720,819...18,732,821
Ensembl chr10:18,720,768...18,732,821

G

peroxisomal biogenesis factor 13

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PEX13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX13 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:23,597,283...23,615,883
Ensembl chr11:23,596,479...23,615,959

G

peroxisomal biogenesis factor 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PEX2 mRNA

NCBI chr 3:5,625,248...5,643,655
Ensembl chr 3:5,625,248...5,641,299

G

phosphofructokinase, platelet

increases expression
multiple interactions

mercuric bromide results in increased expression of PFKP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PFKP mRNA

PMID:26272509 PMID:27188386

NCBI chr13:6,629,910...6,699,096
Ensembl chr13:6,629,804...6,698,813

G

phosphoglucomutase 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PGM5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGM5 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:24,655,625...24,839,206
Ensembl chr19:24,660,380...24,839,219

G

pleckstrin homology like domain, family A, member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PHLDA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:111,342,147...111,344,510
Ensembl chr10:111,342,147...111,344,506

G

pleckstrin homology like domain, family A, member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:143,055,282...143,056,882
Ensembl chr 7:143,055,282...143,056,887

G

peptidase inhibitor 15

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PI15 mRNA

NCBI chr 1:17,672,064...17,701,169
Ensembl chr 1:17,672,125...17,701,163

G

piercer of microtubule wall 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PIERCE2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIERCE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:72,886,999...72,892,658
Ensembl chr 9:72,886,964...72,892,674

G

phosphoinositide-3-kinase regulatory subunit 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PIK3R5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3R5 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:68,322,951...68,388,675
Ensembl chr11:68,322,947...68,388,675

G

phosphatidylinositol-5-phosphate 4-kinase, type II, alpha

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PIP4K2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIP4K2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:18,847,066...19,003,101
Ensembl chr 2:18,847,066...19,002,937

G

pirin

increases expression
multiple interactions

mercuric bromide results in increased expression of PIR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIR mRNA

PMID:26272509 PMID:27188386

NCBI chr X:163,052,427...163,156,009
Ensembl chr X:163,052,367...163,156,007

G

paired-like homeodomain transcription factor 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PITX2 mRNA

NCBI chr 3:128,993,527...129,013,243
Ensembl chr 3:128,993,527...129,013,240

G

polycystic kidney disease 1 like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of PKD1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:117,722,089...117,809,227
Ensembl chr 8:117,722,418...117,809,188

G

Pbx/knotted 1 homeobox 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PKNOX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKNOX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:36,802,278...37,058,637
Ensembl chr 9:36,802,278...37,058,703

G

plakophilin 2

increases expression
multiple interactions

mercuric bromide results in increased expression of PKP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:16,031,209...16,090,576
Ensembl chr16:16,031,182...16,090,576

G

phospholipase A2, group IVA (cytosolic, calcium-dependent)

increases expression
multiple interactions

mercuric bromide results in increased expression of PLA2G4A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041

G

phospholipase C, epsilon 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PLCE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLCE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:38,469,438...38,773,549
Ensembl chr19:38,469,557...38,773,474

G

pleckstrin homology domain-containing, family A (phosphoinositide binding specific) member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of PLEKHA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLEKHA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:25,529,160...25,594,684
Ensembl chr 8:25,529,160...25,592,392

G

polo like kinase 2

increases expression
multiple interactions

mercuric bromide results in increased expression of PLK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

increases expression
multiple interactions

mercuric bromide results in increased expression of PLOD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLOD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:92,421,828...92,490,481
Ensembl chr 9:92,424,276...92,490,481

G

phospholipid scramblase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PLSCR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLSCR1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:92,132,265...92,154,034
Ensembl chr 9:92,131,803...92,154,331

G

plexin C1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PLXNC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:94,626,728...94,780,875
Ensembl chr10:94,626,728...94,780,697

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PMAIP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMAIP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636

G

polymerase (DNA directed), eta (RAD 30 related)

increases expression
multiple interactions

mercuric bromide results in increased expression of POLH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLH mRNA

PMID:26272509 PMID:27188386

NCBI chr17:46,482,281...46,513,567
Ensembl chr17:46,482,281...46,513,571

G

periostin, osteoblast specific factor

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POSTN mRNA

NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458

G

POU domain, class 3, transcription factor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of POU3F1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:124,551,439...124,554,448
Ensembl chr 4:124,550,600...124,554,448

G

POU domain, class 3, transcription factor 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of POU3F2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:22,482,095...22,488,366
Ensembl chr 4:22,482,780...22,488,366

G

POU domain, class 4, transcription factor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of POU4F1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU4F1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:104,699,111...104,705,554
Ensembl chr14:104,699,112...104,705,435

G

protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PPFIA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPFIA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:134,224,521...134,272,493
Ensembl chr 1:134,224,521...134,260,666

G

peptidylprolyl isomerase C

increases expression
multiple interactions

mercuric bromide results in increased expression of PPIC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:53,539,413...53,551,079
Ensembl chr18:53,539,404...53,551,187

G

peptidylprolyl isomerase (cyclophilin)-like 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PPIL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPIL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:16,904,419...16,929,126
Ensembl chr16:16,904,419...16,929,121

G

periplakin

increases expression
multiple interactions

mercuric bromide results in increased expression of PPL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPL mRNA

PMID:26272509 PMID:27188386

NCBI chr16:4,904,155...4,950,345
Ensembl chr16:4,904,155...4,950,285

G

protein phosphatase 1D magnesium-dependent, delta isoform

increases expression
multiple interactions

mercuric bromide results in increased expression of PPM1D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1D mRNA

PMID:26272509 PMID:27188386

NCBI chr11:85,202,080...85,237,897
Ensembl chr11:85,202,070...85,237,892

G

protein phosphatase 1H (PP2C domain containing)

increases expression
multiple interactions

mercuric bromide results in increased expression of PPM1H mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1H mRNA

PMID:26272509 PMID:27188386

NCBI chr10:122,512,720...122,781,700
Ensembl chr10:122,514,667...122,781,700

G

protein phosphatase 1, regulatory subunit 16A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PPP1R16A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R16A mRNA

PMID:26272509 PMID:27188386

NCBI chr15:76,555,843...76,579,119
Ensembl chr15:76,555,815...76,579,119

G

protein phosphatase 1, regulatory subunit 17

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PPP1R17 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R17 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:55,994,482...56,009,674
Ensembl chr 6:55,994,482...56,009,674

G

protein phosphatase 1, regulatory inhibitor subunit 1A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PPP1R1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R1A mRNA

PMID:26272509 PMID:27188386

NCBI chr15:103,438,706...103,446,465
Ensembl chr15:103,438,706...103,446,430

G

protein phosphatase 2, regulatory subunit B, beta

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PPP2R2B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA

PMID:26272509 PMID:27188386

NCBI chr18:42,777,811...43,192,827
Ensembl chr18:42,770,497...43,216,192

G

PR domain containing 1, with ZNF domain

increases expression
multiple interactions

mercuric bromide results in increased expression of PRDM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:44,313,170...44,404,579
Ensembl chr10:44,313,173...44,404,497

G

PR domain containing 5

increases expression
multiple interactions

mercuric bromide results in increased expression of PRDM5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:65,754,640...65,914,606
Ensembl chr 6:65,755,972...65,913,994

G

peroxiredoxin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PRDX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019

G

proline rich membrane anchor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PRIMA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRIMA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:103,160,712...103,208,967
Ensembl chr12:103,163,167...103,208,409

G

protein kinase, cAMP dependent, catalytic, alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of PRKACA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072

G

protein kinase C, beta

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PRKCB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKCB mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625

G

protein kinase C, eta

increases expression
multiple interactions

mercuric bromide results in increased expression of PRKCH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA

PMID:26272509 PMID:27188386

NCBI chr12:73,631,570...73,824,959
Ensembl chr12:73,631,570...73,824,959

G

protein kinase, X-linked

increases expression
multiple interactions

mercuric bromide results in increased expression of PRKX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKX mRNA

PMID:26272509 PMID:27188386

NCBI chr X:76,804,578...76,839,545
Ensembl chr X:76,805,017...76,839,884

G

prion protein

increases expression
multiple interactions

mercuric bromide results in increased expression of PRNP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRNP mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349

G

prokineticin 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PROK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PROK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:99,687,833...99,703,368
Ensembl chr 6:99,688,260...99,703,353

G

prolyl-tRNA synthetase domain containing 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRORSD1P mRNA

NCBI chr11:29,461,757...29,465,033
Ensembl chr11:29,461,757...29,465,033

G

proline and serine rich 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PROSER2 mRNA

NCBI chr 2:6,103,304...6,135,100
Ensembl chr 2:6,102,418...6,135,022

G

proline rich Gla (G-carboxyglutamic acid) 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PRRG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRRG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:77,493,216...77,627,539
Ensembl chr X:77,493,219...77,627,502

G

serine protease 12 neurotrypsin (motopsin)

increases expression
multiple interactions

mercuric bromide results in increased expression of PRSS12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:123,240,562...123,300,251
Ensembl chr 3:123,240,562...123,300,246

G

serine protease 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS2 mRNA

NCBI chr 6:41,498,710...41,502,013
Ensembl chr 6:41,498,721...41,502,013

G

serine protease 23

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PRSS23 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:89,156,988...89,176,399
Ensembl chr 7:89,156,991...89,176,395

G

serine protease 8 (prostasin)

increases expression
multiple interactions

mercuric bromide results in increased expression of PRSS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRSS8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:127,524,889...127,529,266
Ensembl chr 7:127,524,888...127,529,276

G

prune homolog 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PRUNE2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRUNE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:16,933,033...17,201,322
Ensembl chr19:16,933,482...17,201,296

G

proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PSMB8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PSMB8 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:34,417,169...34,420,428
Ensembl chr17:34,416,695...34,420,428

G

prostaglandin E receptor 4 (subtype EP4)

increases expression
multiple interactions

mercuric bromide results in increased expression of PTGER4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTGER4 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:5,262,880...5,273,668
Ensembl chr15:5,236,142...5,273,668

G

prostaglandin-endoperoxide synthase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PTGS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284

G

protein tyrosine phosphatase 4a3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PTP4A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTP4A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:73,594,991...73,629,075
Ensembl chr15:73,594,994...73,630,615

G

pentraxin related gene

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTX3 mRNA

NCBI chr 3:66,127,308...66,133,227
Ensembl chr 3:66,127,331...66,133,226

G

Pvt1 oncogene

increases expression
multiple interactions

mercuric bromide results in increased expression of PVT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PVT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:61,909,835...62,132,064
Ensembl chr15:61,909,817...62,249,945

G

PWWP domain containing 2B

increases expression
multiple interactions

mercuric bromide results in increased expression of PWWP2B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:138,828,398...138,847,172
Ensembl chr 7:138,828,398...138,849,819

G

PX domain containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of PXDC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:34,811,823...34,836,664
Ensembl chr13:34,811,817...34,837,469

G

muscle glycogen phosphorylase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of PYGM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PYGM mRNA

PMID:26272509 PMID:27188386

NCBI chr19:6,434,438...6,448,494
Ensembl chr19:6,434,429...6,448,489

G

RAB17, member RAS oncogene family

increases expression
multiple interactions

mercuric bromide results in increased expression of RAB17 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:90,885,855...90,897,395
Ensembl chr 1:90,885,855...90,897,383

G

RAB20, member RAS oncogene family

increases expression
multiple interactions

mercuric bromide results in increased expression of RAB20 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:11,503,390...11,528,640
Ensembl chr 8:11,503,518...11,528,710

G

RAB33A, member RAS oncogene family

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RAB33A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA

PMID:26272509 PMID:27188386

NCBI chr X:47,602,540...47,619,112
Ensembl chr X:47,608,162...47,619,109

G

retinoic acid induced 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAI2 mRNA

NCBI chr X:160,500,032...160,562,490
Ensembl chr X:160,500,065...160,562,492

G

retinoic acid receptor, beta

increases expression
multiple interactions

mercuric bromide results in increased expression of RARB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARB mRNA

PMID:26272509 PMID:27188386

NCBI chr14:5,387,365...6,038,924
Ensembl chr14:5,650,540...6,038,924

G

RAS and EF hand domain containing

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA

NCBI chr 4:73,632,814...73,709,382
Ensembl chr 4:73,632,816...73,709,231

G

RAS protein-specific guanine nucleotide-releasing factor 2

increases expression
multiple interactions

mercuric bromide results in increased expression of RASGRF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASGRF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:92,028,526...92,268,584
Ensembl chr13:92,028,519...92,268,164

G

Ras association (RalGDS/AF-6) domain family member 6

increases expression
multiple interactions

mercuric bromide results in increased expression of RASSF6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASSF6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:90,750,933...90,788,594
Ensembl chr 5:90,750,935...90,788,516

G

RNA binding protein, fox-1 homolog (C. elegans) 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RBFOX3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:118,380,586...118,802,423
Ensembl chr11:118,380,588...118,802,423

G

RNA binding motif protein 20

increases expression
multiple interactions

mercuric bromide results in increased expression of RBM20 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM20 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:53,649,422...53,855,514
Ensembl chr19:53,665,737...53,855,511

G

RNA binding motif protein 47

increases expression
multiple interactions

mercuric bromide results in increased expression of RBM47 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:66,173,892...66,309,297
Ensembl chr 5:66,173,892...66,330,461

G

RNA binding motif, single stranded interacting protein

increases expression
multiple interactions

mercuric bromide results in increased expression of RBMS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:116,401,814...117,869,900
Ensembl chr 9:116,401,814...117,701,749

G

retinol binding protein 7, cellular

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RBP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBP7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:149,534,144...149,550,919
Ensembl chr 4:149,534,144...149,539,435

G

receptor accessory protein 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of REEP6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REEP6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:80,165,831...80,172,275
Ensembl chr10:80,165,787...80,172,275

G

reelin

increases expression
multiple interactions

mercuric bromide results in increased expression of RELN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RELN mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:22,089,452...22,549,703
Ensembl chr 5:22,089,452...22,549,700

G

RALBP1 associated Eps domain containing protein 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REPS2 mRNA

NCBI chr X:161,194,949...161,426,701
Ensembl chr X:161,194,950...161,426,645

G

ret proto-oncogene

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RET mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RET mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:118,128,709...118,174,705
Ensembl chr 6:118,128,706...118,174,679

G

reticulophagy regulator 1

increases expression
multiple interactions

mercuric bromide results in increased expression of RETREG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RETREG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:25,840,795...25,973,782
Ensembl chr15:25,843,266...25,973,773

G

REV3 like, DNA directed polymerase zeta catalytic subunit

increases expression
multiple interactions

mercuric bromide results in increased expression of REV3L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REV3L mRNA

PMID:26272509 PMID:27188386

NCBI chr10:39,607,557...39,751,207
Ensembl chr10:39,608,114...39,751,207

G

refilin B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RFLNB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFLNB mRNA

PMID:26272509 PMID:27188386

NCBI chr11:75,910,020...75,918,608
Ensembl chr11:75,910,020...75,918,608

G

regulatory factor X, 2 (influences HLA class II expression)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RFX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:57,082,897...57,138,102
Ensembl chr17:57,082,897...57,138,013

G

regulatory factor X, 4 (influences HLA class II expression)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RFX4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX4 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:84,591,895...84,742,402
Ensembl chr10:84,591,926...84,742,402

G

repulsive guidance molecule family member A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RGMA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:73,025,268...73,069,647
Ensembl chr 7:73,025,257...73,069,647

G

repulsive guidance molecule family member B

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMB mRNA

NCBI chr17:16,024,923...16,051,508
Ensembl chr17:16,023,450...16,051,301

G

regulator of G-protein signaling 5

increases expression
multiple interactions

mercuric bromide results in increased expression of RGS5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:169,483,070...169,523,367
Ensembl chr 1:169,483,070...169,523,382

G

regulator of G protein signaling 7

increases expression
multiple interactions

mercuric bromide results in increased expression of RGS7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:174,886,642...175,320,287
Ensembl chr 1:174,886,653...175,320,066

G

ras homolog family member B

increases expression
multiple interactions

mercuric bromide results in increased expression of RHOB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA

PMID:26272509 PMID:27188386

NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009

G

Rho-related BTB domain containing 3

increases expression
multiple interactions

mercuric bromide results in increased expression of RHOBTB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:76,017,656...76,092,054
Ensembl chr13:76,017,656...76,092,044

G

receptor-interacting serine-threonine kinase 4

increases expression
multiple interactions

mercuric bromide results in increased expression of RIPK4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPK4 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:97,543,133...97,564,979
Ensembl chr16:97,543,133...97,564,987

G

RHO family interacting cell polarization regulator 2

increases expression
multiple interactions

mercuric bromide results in increased expression of RIPOR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIPOR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:24,685,513...24,917,789
Ensembl chr13:24,685,508...24,917,799

G

ripply transcriptional repressor 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIPPLY3 mRNA

NCBI chr16:94,129,281...94,137,794
Ensembl chr16:94,129,279...94,137,794

G

rhabdomyosarcoma 2 associated transcript (non-coding RNA)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RMST mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA

PMID:26272509 PMID:27188386

NCBI chr10:91,917,608...92,001,040
Ensembl chr10:91,906,899...92,001,132

G

Rho family GTPase 3

increases expression
multiple interactions

mercuric bromide results in increased expression of RND3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RND3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:51,020,451...51,039,123
Ensembl chr 2:51,020,450...51,039,123

G

ring finger protein 125

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RNF125 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF125 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:21,077,672...21,120,416
Ensembl chr18:21,077,682...21,116,919

G

ring finger protein 130

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RNF130 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF130 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:49,916,158...50,016,546
Ensembl chr11:49,916,173...50,016,546

G

ring finger protein 144B

increases expression
multiple interactions

mercuric bromide results in increased expression of RNF144B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA

PMID:26272509 PMID:27188386

NCBI chr13:47,276,196...47,401,470
Ensembl chr13:47,276,132...47,401,467

G

ring finger protein 217

increases expression
multiple interactions

mercuric bromide results in increased expression of RNF217 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:31,377,883...31,485,721
Ensembl chr10:31,369,189...31,485,180

G

ring finger protein, transmembrane 1

increases expression
multiple interactions

mercuric bromide results in increased expression of RNFT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNFT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:86,375,483...86,389,833
Ensembl chr11:86,375,483...86,389,851

G

roundabout guidance receptor 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ROBO3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:37,327,341...37,344,730
Ensembl chr 9:37,326,965...37,344,542

G

reprimo, TP53 dependent G2 arrest mediator candidate

increases expression
multiple interactions

mercuric bromide results in increased expression of RPRM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:53,974,105...53,975,564
Ensembl chr 2:53,974,105...53,975,564

G

ribosomal protein S27-like

increases expression
multiple interactions

mercuric bromide results in increased expression of RPS27L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS27L mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798

G

related RAS viral (r-ras) oncogene

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RRAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RRAS mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:44,665,686...44,671,070
Ensembl chr 7:44,667,385...44,671,071

G

ribosomal protein S6 kinase related

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RSKR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSKR mRNA

PMID:26272509 PMID:27188386

NCBI chr11:78,181,580...78,187,631
Ensembl chr11:78,181,667...78,187,631

G

radial spoke head 9 homolog (Chlamydomonas)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RSPH9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPH9 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:46,432,964...46,455,171
Ensembl chr17:46,432,961...46,455,142

G

R-spondin 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RSPO2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:42,884,184...43,034,990
Ensembl chr15:42,884,190...43,034,222

G

RUN domain containing 3B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of RUNDC3B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RUNDC3B mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:8,540,336...8,673,079
Ensembl chr 5:8,540,334...8,672,952

G

RUNX1 translocation partner 1

increases expression

mercuric bromide results in increased expression of RUNX1T1 mRNA

NCBI chr 4:13,742,628...13,895,056
Ensembl chr 4:13,743,436...13,893,649

G

runt related transcription factor 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA

NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684

G

S100 calcium binding protein A10 (calpactin)

increases expression
multiple interactions

mercuric bromide results in increased expression of S100A10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:93,462,424...93,471,952
Ensembl chr 3:93,462,387...93,471,950

G

S100 calcium binding protein A11

increases expression
multiple interactions

mercuric bromide results in increased expression of S100A11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:93,427,803...93,433,595
Ensembl chr 3:93,427,795...93,433,594

G

S100 calcium binding protein A14

increases expression
multiple interactions

mercuric bromide results in increased expression of S100A14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:90,434,156...90,436,144
Ensembl chr 3:90,434,163...90,436,144

G

spalt like transcription factor 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SALL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:81,010,204...81,030,236
Ensembl chr18:81,009,591...81,029,986

G

sterile alpha motif domain containing 13

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SAMD13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMD13 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:146,350,944...146,391,555
Ensembl chr 3:146,350,950...146,391,347
Ensembl chr 3:146,350,950...146,391,347

G

sterile alpha motif domain containing 4

increases expression
multiple interactions

mercuric bromide results in increased expression of SAMD4A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAMD4A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:47,120,414...47,343,274
Ensembl chr14:47,120,311...47,343,272

G

SAM domain and HD domain, 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SAMHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMHD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:156,939,454...156,977,016
Ensembl chr 2:156,939,453...156,977,185

G

secretion associated Ras related GTPase 1B

increases expression
multiple interactions

mercuric bromide results in increased expression of SAR1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAR1B mRNA

PMID:26272509 PMID:27188386

NCBI chr11:51,654,490...51,682,780
Ensembl chr11:51,654,514...51,682,752

G

spermidine/spermine N1-acetyl transferase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SAT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:153,996,128...153,999,345
Ensembl chr X:153,996,128...153,999,445

G

special AT-rich sequence binding protein 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SATB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:56,833,145...57,019,350
Ensembl chr 1:56,833,140...57,017,809

G

SET binding factor 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SBF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SBF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:109,907,218...110,215,150
Ensembl chr 7:109,907,220...110,214,129

G

scinderin

increases expression
multiple interactions

mercuric bromide results in increased expression of SCIN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCIN mRNA

PMID:26272509 PMID:27188386

NCBI chr12:40,109,768...40,184,227
Ensembl chr12:40,109,768...40,184,227

G

sodium channel, voltage-gated, type II, alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of SCN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:65,451,108...65,597,791
Ensembl chr 2:65,451,115...65,597,791

G

sodium channel, nonvoltage-gated 1 alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of SCNN1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:125,286,657...125,321,906
Ensembl chr 6:125,297,622...125,321,906

G

signal peptide, CUB domain, EGF-like 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SCUBE2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:109,397,897...109,464,886
Ensembl chr 7:109,397,883...109,464,886

G

selenoprotein M

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SELENOM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOM mRNA

PMID:26272509 PMID:27188386

NCBI chr11:3,464,684...3,467,351
Ensembl chr11:3,464,684...3,467,351

G

selenoprotein P

increases expression
multiple interactions

mercuric bromide results in increased expression of SELENOP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SELENOP mRNA

PMID:26272509 PMID:27188386

NCBI chr15:3,300,249...3,309,992
Ensembl chr15:3,298,029...3,309,990

G

selenoprotein W

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SELENOW mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOW mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:15,651,133...15,656,296
Ensembl chr 7:15,651,133...15,656,327

G

sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C

increases expression
multiple interactions

mercuric bromide results in increased expression of SEMA3C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:17,779,814...17,935,266
Ensembl chr 5:17,779,279...17,935,266

G

sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E

increases expression
multiple interactions

mercuric bromide results in increased expression of SEMA3E mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:14,075,290...14,306,703
Ensembl chr 5:14,075,290...14,306,703

G

sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A

increases expression

mercuric bromide results in increased expression of SEMA6A mRNA

NCBI chr18:47,378,321...47,504,267
Ensembl chr18:47,368,665...47,501,937

G

serine (or cysteine) peptidase inhibitor, clade B, member 1a

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SERPINB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:33,026,075...33,037,189
Ensembl chr13:33,026,075...33,035,168

G

serine (or cysteine) peptidase inhibitor, clade B, member 9

increases expression
multiple interactions

mercuric bromide results in increased expression of SERPINB9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:33,181,044...33,201,938
Ensembl chr13:33,187,233...33,201,940

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SERPINE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

serine (or cysteine) peptidase inhibitor, clade I, member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SERPINI1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:75,464,800...75,549,830
Ensembl chr 3:75,464,854...75,550,802

G

sestrin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SESN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SESN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:41,686,570...41,784,432
Ensembl chr10:41,685,931...41,784,420

G

sestrin 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SESN2 mRNA

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

seizure related gene 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SEZ6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEZ6 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:77,821,403...77,869,874
Ensembl chr11:77,821,626...77,869,874

G

stratifin

increases expression
multiple interactions

mercuric bromide results in increased expression of SFN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479

G

secreted frizzled-related protein 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SFRP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:23,901,401...23,939,648
Ensembl chr 8:23,901,518...23,939,648

G

sideroflexin 5

increases expression
multiple interactions

mercuric bromide results in increased expression of SFXN5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFXN5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:85,190,031...85,310,488
Ensembl chr 6:85,190,031...85,310,404

G

serum/glucocorticoid regulated kinase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SGK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802

G

serum/glucocorticoid regulated kinase 3

increases expression
multiple interactions

mercuric bromide results in increased expression of SGK3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:9,868,355...9,972,795
Ensembl chr 1:9,868,332...9,971,070

G

sphingosine-1-phosphate phosphatase 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA

NCBI chr 1:78,286,186...78,396,926
Ensembl chr 1:78,286,982...78,396,926

G

SH2 domain containing 4A

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH2D4A mRNA

NCBI chr 8:68,729,180...68,800,356
Ensembl chr 8:68,729,219...68,800,351

G

src homology 2 domain-containing transforming protein C3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA

NCBI chr13:51,577,422...51,724,909
Ensembl chr13:51,585,077...51,723,523

G

shisa family member 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SHISA6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISA6 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:66,102,551...66,418,715
Ensembl chr11:66,102,551...66,416,790

G

shisa like 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SHISAL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:84,263,404...84,367,061
Ensembl chr15:84,263,404...84,331,298

G

shootin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SHTN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:58,961,790...59,064,536
Ensembl chr19:58,961,788...59,064,532

G

signal-induced proliferation-associated 1 like 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SIPA1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIPA1L2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:126,144,807...126,296,602
Ensembl chr 8:126,144,802...126,296,547

G

sine oculis-related homeobox 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SIX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:73,088,601...73,093,486
Ensembl chr12:73,086,789...73,100,661

G

sine oculis-related homeobox 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA

NCBI chr17:85,921,036...85,933,619
Ensembl chr17:85,921,036...85,936,730

G

sine oculis-related homeobox 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SIX5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:18,828,469...18,832,474
Ensembl chr 7:18,828,519...18,832,474

G

sine oculis-related homeobox 6

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX6 mRNA

NCBI chr12:72,986,656...72,991,673
Ensembl chr12:72,986,666...72,991,673

G

SKI/DACH domain containing 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SKIDA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKIDA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:18,048,510...18,053,627
Ensembl chr 2:18,045,487...18,053,862

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 4

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC10A4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC10A4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:73,164,247...73,170,298
Ensembl chr 5:73,164,226...73,170,298

G

solute carrier family 16 (monocarboxylic acid transporters), member 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SLC16A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:120,839,310...120,849,826
Ensembl chr11:120,839,306...120,851,694

G

solute carrier family 18 (vesicular monoamine), member 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SLC18A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC18A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444

G

solute carrier family 1 (glial high affinity glutamate transporter), member 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SLC1A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC1A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:102,488,584...102,621,129
Ensembl chr 2:102,489,004...102,621,129

G

solute carrier family 1 (glutamate/neutral amino acid transporter), member 4

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC1A4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A4 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:20,252,180...20,282,713
Ensembl chr11:20,252,180...20,282,713

G

solute carrier family 22 (organic anion/cation transporter), member 15

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC22A15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC22A15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:101,763,084...101,831,769
Ensembl chr 3:101,763,092...101,831,769

G

solute carrier family 25, member 53

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SLC25A53 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A53 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:135,881,865...135,939,051
Ensembl chr X:135,881,865...135,939,051

G

solute carrier family 27 (fatty acid transporter), member 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A2 mRNA

NCBI chr 2:126,394,944...126,430,163
Ensembl chr 2:126,394,327...126,430,163

G

solute carrier family 2 (facilitated glucose transporter), member 3

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC2A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599

G

solute carrier family 30 (zinc transporter), member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC30A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359

G

solute carrier family 35, member G2

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC35G2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:100,431,178...100,453,138
Ensembl chr 9:100,434,241...100,453,143

G

solute carrier family 38, member 6

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC38A6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:73,333,622...73,408,772
Ensembl chr12:73,333,553...73,400,823

G

solute carrier family 39 (metal ion transporter), member 8

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC39A8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:135,522,644...135,594,333
Ensembl chr 3:135,531,040...135,594,333

G

solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC3A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733

G

solute carrier family 40 (iron-regulated transporter), member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC40A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

solute carrier family 44, member 3

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC44A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC44A3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:121,253,177...121,325,993
Ensembl chr 3:121,253,177...121,326,053

G

solute carrier family 6 (neurotransmitter transporter), member 15

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SLC6A15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A15 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:103,203,320...103,255,240
Ensembl chr10:103,203,644...103,255,238

G

solute carrier family 6 (neurotransmitter transporter, creatine), member 8

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SLC6A8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:72,716,739...72,726,108
Ensembl chr X:72,716,756...72,726,108

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC7A11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC7A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:41,315,404...41,375,107
Ensembl chr 8:41,315,433...41,375,345

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5

increases expression
multiple interactions

mercuric bromide results in increased expression of SLC7A5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 7

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A7 mRNA

NCBI chr14:54,606,899...54,657,525
Ensembl chr14:54,606,899...54,655,237

G

solute carrier organic anion transporter family, member 4C1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA

NCBI chr 1:96,744,918...96,800,027
Ensembl chr 1:96,743,995...96,799,896

G

schlafen 3

multiple interactions
increases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLFN12 mRNA
mercuric bromide results in increased expression of SLFN12 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:83,082,156...83,105,980
Ensembl chr11:83,082,156...83,105,980

G

slit guidance ligand 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SLIT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:48,138,633...48,465,077
Ensembl chr 5:48,140,480...48,465,075

G

slit guidance ligand 3

increases expression
multiple interactions

mercuric bromide results in increased expression of SLIT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:35,012,283...35,599,334
Ensembl chr11:35,012,051...35,599,334

G

SLIT and NTRK-like family, member 1

decreases expression

mercuric bromide results in decreased expression of SLITRK1 mRNA

NCBI chr14:109,147,420...109,151,671
Ensembl chr14:109,146,232...109,151,590

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SMARCA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:26,582,578...26,755,721
Ensembl chr19:26,582,450...26,755,722

G

SPARC related modular calcium binding 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SMOC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:81,073,582...81,233,188
Ensembl chr12:81,073,582...81,233,188

G

SPARC related modular calcium binding 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SMOC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMOC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:14,499,768...14,625,052
Ensembl chr17:14,499,768...14,625,052

G

sphingomyelin phosphodiesterase, acid-like 3A

increases expression
multiple interactions

mercuric bromide results in increased expression of SMPDL3A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMPDL3A mRNA

PMID:26272509 PMID:27188386

NCBI chr10:57,670,640...57,687,926
Ensembl chr10:57,670,431...57,687,926

G

snail family zinc finger 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SNAI2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:14,523,716...14,527,259
Ensembl chr16:14,523,716...14,527,249

G

synaptosomal-associated protein 91

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SNAP91 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNAP91 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:86,647,976...86,762,766
Ensembl chr 9:86,647,976...86,762,707

G

synuclein, alpha

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SNCA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCA mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

synuclein, alpha interacting protein (synphilin)

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SNCAIP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA

PMID:26272509 PMID:27188386

NCBI chr18:52,900,872...53,049,007
Ensembl chr18:52,900,781...53,049,007

G

small nucleolar RNA host gene 14

decreases expression

mercuric bromide results in decreased expression of SNHG14 mRNA

NCBI chr 7:58,922,485...60,099,925

G

sine oculis binding protein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SOBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOBP mRNA

PMID:26272509 PMID:27188386

NCBI chr10:42,878,484...43,059,144
Ensembl chr10:42,878,496...43,050,526

G

suppressor of cytokine signaling 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SOCS2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOCS2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:95,219,765...95,253,176
Ensembl chr10:95,221,224...95,253,042

G

sortilin-related VPS10 domain containing receptor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SORCS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:50,131,733...50,668,030
Ensembl chr19:50,131,737...50,667,084

G

sclerostin

increases expression
multiple interactions

mercuric bromide results in increased expression of SOST mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA

PMID:26272509 PMID:27188386

NCBI chr11:101,853,284...101,857,841
Ensembl chr11:101,853,284...101,857,841

G

SRY (sex determining region Y)-box 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:12,445,519...12,449,555
Ensembl chr 8:12,445,295...12,450,126

G

SRY (sex determining region Y)-box 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SOX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610

G

SRY (sex determining region Y)-box 21, opposite strand 1

decreases expression

mercuric bromide results in decreased expression of SOX21-AS1 mRNA

NCBI chr14:118,473,644...118,498,611
Ensembl chr14:118,473,644...118,498,611

G

SOX2 overlapping transcript (non-protein coding)

multiple interactions
decreases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA
mercuric bromide results in decreased expression of SOX2-OT mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:34,614,530...34,732,142
Ensembl chr 3:34,158,419...34,736,768

G

SRY (sex determining region Y)-box 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SOX6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:115,070,107...115,639,186
Ensembl chr 7:115,070,107...115,638,031

G

trans-acting transcription factor 5

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP5 mRNA

NCBI chr 2:70,305,267...70,308,070
Ensembl chr 2:70,305,267...70,308,073

G

sperm associated antigen 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SPAG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPAG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:36,175,629...36,235,767
Ensembl chr15:36,178,245...36,235,767

G

sperm associated antigen 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SPAG4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:155,907,108...155,911,421
Ensembl chr 2:155,907,095...155,912,537

G

sperm associated antigen 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SPAG6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPAG6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:18,698,808...18,754,561
Ensembl chr 2:18,698,843...18,755,224

G

spondin 1, (f-spondin) extracellular matrix protein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SPON1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPON1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:113,365,235...113,642,610
Ensembl chr 7:113,365,235...113,642,605

G

secreted phosphoprotein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SPP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

sprouty RTK signaling antagonist 4

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPRY4 mRNA

NCBI chr18:38,719,300...38,734,400
Ensembl chr18:38,719,300...38,734,468

G

splA/ryanodine receptor domain and SOCS box containing 4

increases expression
multiple interactions

mercuric bromide results in increased expression of SPSB4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPSB4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:96,825,535...96,900,408
Ensembl chr 9:96,825,535...96,900,896

G

serine palmitoyltransferase, long chain base subunit 3

increases expression
multiple interactions

mercuric bromide results in increased expression of SPTLC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPTLC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:139,335,833...139,478,981
Ensembl chr 2:139,335,833...139,479,594

G

squalene epoxidase

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SQLE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SQLE mRNA

PMID:26272509 PMID:27188386

NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041

G

sequestosome 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SQSTM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQSTM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

SRC kinase signaling inhibitor 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SRCIN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:97,400,166...97,466,059
Ensembl chr11:97,400,166...97,467,012

G

sulfiredoxin 1 homolog (S. cerevisiae)

increases expression
multiple interactions

mercuric bromide results in increased expression of SRXN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRXN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296

G

somatostatin

increases expression
multiple interactions

mercuric bromide results in increased expression of SST mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA

PMID:26272509 PMID:27188386

NCBI chr16:23,708,327...23,710,041
Ensembl chr16:23,708,323...23,709,708

G

suppression of tumorigenicity 14 (colon carcinoma)

increases expression
multiple interactions

mercuric bromide results in increased expression of ST14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:30,999,886...31,043,138
Ensembl chr 9:31,000,698...31,043,149

G

beta galactoside alpha 2,6 sialyltransferase 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ST6GAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GAL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:55,752,071...55,821,582
Ensembl chr17:55,752,383...55,821,582

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

increases expression
multiple interactions

mercuric bromide results in increased expression of ST8SIA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ST8SIA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:95,515,407...95,595,473
Ensembl chr 1:95,515,407...95,595,296

G

signal transducing adaptor molecule (SH3 domain and ITAM motif) 2

increases expression
multiple interactions

mercuric bromide results in increased expression of STAM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STAM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:52,582,213...52,632,212
Ensembl chr 2:52,581,676...52,632,293

G

stanniocalcin 2

increases expression
multiple interactions

mercuric bromide results in increased expression of STC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:31,309,441...31,320,061
Ensembl chr11:31,307,307...31,320,074

G

six transmembrane epithelial antigen of the prostate 1

increases expression
multiple interactions

mercuric bromide results in increased expression of STEAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:5,786,322...5,799,317
Ensembl chr 5:5,786,317...5,799,326

G

serine/threonine kinase 32A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of STK32A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA

PMID:26272509 PMID:27188386

NCBI chr18:43,340,762...43,450,546
Ensembl chr18:43,340,648...43,451,747

G

storkhead box 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of STOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:62,494,822...62,561,907
Ensembl chr10:62,494,822...62,561,907

G

steroid sulfatase

increases expression
multiple interactions

mercuric bromide results in increased expression of STS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STS mRNA

PMID:26272509 PMID:27188386

NCBI chr X:168,856,332...169,015,037
Ensembl chr X:168,909,030...169,014,924

G

STT3, subunit of the oligosaccharyltransferase complex, homolog B (S. cerevisiae)

decreases expression

mercuric bromide results in decreased expression of STT3B mRNA

NCBI chr 9:115,071,538...115,139,536
Ensembl chr 9:115,071,649...115,139,489

G

syntaxin 3

increases expression
multiple interactions

mercuric bromide results in increased expression of STX3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:11,752,482...11,798,933
Ensembl chr19:11,752,482...11,796,767

G

serine/threonine/tyrosine kinase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of STYK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:131,276,096...131,330,532
Ensembl chr 6:131,276,105...131,330,560

G

sulfatase 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SULF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SULF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:12,762,421...12,946,090
Ensembl chr 1:12,762,501...12,931,416

G

sulfatase 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SULF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULF2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:165,915,819...165,997,603
Ensembl chr 2:165,915,009...165,997,583

G

sulfotransferase family 1A, phenol-preferring, member 1

multiple interactions
increases expression

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA
mercuric bromide results in increased expression of SULT1A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:126,272,042...126,289,615
Ensembl chr 7:126,272,037...126,275,604

G

synaptic vesicle glycoprotein 2c

decreases expression

mercuric bromide results in decreased expression of SV2C mRNA

NCBI chr13:96,091,102...96,270,837
Ensembl chr13:96,091,102...96,269,085

G

syntabulin (syntaxin-interacting)

increases expression
multiple interactions

mercuric bromide results in increased expression of SYBU mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYBU mRNA

PMID:26272509 PMID:27188386

NCBI chr15:44,535,252...44,651,466
Ensembl chr15:44,535,252...44,651,459

G

spectrin repeat containing, nuclear envelope 1

increases expression
multiple interactions

mercuric bromide results in increased expression of SYNE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:4,970,192...5,501,013
Ensembl chr10:4,970,917...5,501,482

G

synaptogyrin 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SYNGR3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNGR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:24,904,066...24,908,923
Ensembl chr17:24,904,066...24,908,929

G

synaptojanin 2

increases expression
multiple interactions

mercuric bromide results in increased expression of SYNJ2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNJ2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:5,991,555...6,106,041
Ensembl chr17:5,991,555...6,094,565

G

synaptoporin

increases expression
multiple interactions

mercuric bromide results in increased expression of SYNPR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNPR mRNA

PMID:26272509 PMID:27188386

NCBI chr14:8,854,294...9,184,983
Ensembl chr14:8,853,423...9,184,983

G

synaptotagmin IX

decreases expression
multiple interactions

mercuric bromide results in decreased expression of SYT9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:106,969,929...107,147,863
Ensembl chr 7:106,969,935...107,147,863

G

tachykinin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TAC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834

G

transforming, acidic coiled-coil containing protein 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:25,644,568...25,730,901
Ensembl chr 8:25,644,568...25,746,604

G

tumor-associated calcium signal transducer 2

increases expression
multiple interactions

mercuric bromide results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:67,511,043...67,512,806
Ensembl chr 6:67,511,046...67,512,780

G

TAFA chemokine like family member 2

increases expression
multiple interactions

mercuric bromide results in increased expression of TAFA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:123,099,813...123,577,109
Ensembl chr10:123,099,901...123,577,109

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TANC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TANC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:59,442,167...59,676,557
Ensembl chr 2:59,442,386...59,676,493

G

tandem C2 domains, nuclear

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA

NCBI chr12:101,611,705...101,685,178
Ensembl chr12:101,611,702...101,684,782

G

testis development related protein

increases expression
multiple interactions

mercuric bromide results in increased expression of TDRP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDRP mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:14,002,008...14,025,484
Ensembl chr 8:14,002,008...14,025,032

G

tektin 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TEKT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEKT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:126,215,914...126,219,481
Ensembl chr 4:126,215,914...126,219,481

G

terminal nucleotidyltransferase 5C

increases expression
multiple interactions

mercuric bromide results in increased expression of TENT5C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5C mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:100,375,373...100,396,508
Ensembl chr 3:100,358,944...100,396,640

G

testin LIM domain protein

increases expression
multiple interactions

mercuric bromide results in increased expression of TES mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:17,065,148...17,105,824
Ensembl chr 6:17,065,148...17,105,827

G

testis expressed gene 19.2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TEX19 mRNA

NCBI chr11:121,007,041...121,009,503
Ensembl chr11:121,007,041...121,009,503

G

transcription factor AP-2, alpha

increases expression
multiple interactions

mercuric bromide results in increased expression of TFAP2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA

PMID:26272509 PMID:27188386

NCBI chr13:40,867,278...40,891,715
Ensembl chr13:40,868,778...40,891,852

G

transcription factor AP-2 beta

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA

NCBI chr 1:19,279,132...19,309,071
Ensembl chr 1:19,279,138...19,308,800

G

transcription factor AP-2, gamma

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA

NCBI chr 2:172,387,599...172,400,542
Ensembl chr 2:172,391,513...172,400,542

G

transcription factor E3

increases expression
multiple interactions

mercuric bromide results in increased expression of TFE3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFE3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:7,628,769...7,641,441
Ensembl chr X:7,628,799...7,641,441

G

tissue factor pathway inhibitor

increases expression
multiple interactions

mercuric bromide results in increased expression of TFPI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:84,263,199...84,307,119
Ensembl chr 2:84,263,199...84,307,119

G

tissue factor pathway inhibitor 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI2 mRNA

NCBI chr 6:3,962,589...3,988,977
Ensembl chr 6:3,962,595...3,988,919

G

transforming growth factor beta 1 induced transcript 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB1I1 mRNA

NCBI chr 7:127,845,963...127,852,884
Ensembl chr 7:127,845,984...127,854,871

G

thyroid adenoma associated

decreases expression

mercuric bromide results in decreased expression of THADA mRNA

NCBI chr17:84,497,484...84,773,674
Ensembl chr17:84,497,504...84,773,633

G

thrombospondin 1

increases expression
multiple interactions

mercuric bromide results in increased expression of THBS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614

G

thrombospondin, type I, domain containing 7A

increases expression
multiple interactions

mercuric bromide results in increased expression of THSD7A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD7A mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:12,311,607...12,749,252
Ensembl chr 6:12,311,609...12,749,409

G

THUMP domain containing 3

increases expression
multiple interactions

mercuric bromide results in increased expression of THUMPD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THUMPD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:113,023,292...113,045,239
Ensembl chr 6:113,023,186...113,045,234

G

TINCR ubiquitin domain containing

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TINCR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TINCR mRNA

PMID:26272509 PMID:27188386

NCBI chr17:56,858,414...56,861,403
Ensembl chr17:56,858,414...56,861,439

G

tight junction protein 2

increases expression
multiple interactions

mercuric bromide results in increased expression of TJP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TJP2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:24,071,860...24,202,492
Ensembl chr19:24,071,869...24,202,394

G

transketolase

increases expression
multiple interactions

mercuric bromide results in increased expression of TKT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKT mRNA

PMID:26272509 PMID:27188386

NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677

G

transmembrane protein 132D

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TMEM132D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM132D mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:127,860,555...128,510,141
Ensembl chr 5:127,858,694...128,510,141

G

transmembrane protein 132E

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TMEM132E mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM132E mRNA

PMID:26272509 PMID:27188386

NCBI chr11:82,279,281...82,338,447
Ensembl chr11:82,279,726...82,337,158

G

transmembrane protein 144

increases expression
multiple interactions

mercuric bromide results in increased expression of TMEM144 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:79,719,871...79,760,093
Ensembl chr 3:79,719,871...79,760,080

G

transmembrane protein 150C

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM150C mRNA

NCBI chr 5:100,225,731...100,313,463
Ensembl chr 5:100,225,731...100,307,667

G

transmembrane protein 154

increases expression
multiple interactions

mercuric bromide results in increased expression of TMEM154 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM154 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:84,573,499...84,611,882
Ensembl chr 3:84,573,499...84,611,882

G

transmembrane protein 163

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TMEM163 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:127,418,079...127,605,758
Ensembl chr 1:127,414,283...127,607,285

G

transmembrane protein 218

decreases expression

mercuric bromide results in decreased expression of TMEM218 mRNA

NCBI chr 9:37,119,519...37,134,524
Ensembl chr 9:37,119,519...37,135,996

G

transmembrane protein 231

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TMEM231 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM231 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:112,638,639...112,660,445
Ensembl chr 8:112,638,643...112,660,513

G

transmembrane protein 30B

increases expression
multiple interactions

mercuric bromide results in increased expression of TMEM30B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA

PMID:26272509 PMID:27188386

NCBI chr12:73,589,888...73,593,169
Ensembl chr12:73,590,176...73,593,166

G

transmembrane protein 37

increases expression
multiple interactions

mercuric bromide results in increased expression of TMEM37 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM37 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:119,995,106...120,001,799
Ensembl chr 1:119,995,107...120,001,804

G

transmembrane protein 40

increases expression
multiple interactions

mercuric bromide results in increased expression of TMEM40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM40 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:115,706,092...115,739,427
Ensembl chr 6:115,706,092...115,739,371

G

transmembrane protein 63a

increases expression
multiple interactions

mercuric bromide results in increased expression of TMEM63A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM63A mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:180,769,899...180,802,671
Ensembl chr 1:180,769,909...180,802,677

G

transmembrane protein 74

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TMEM74 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:43,726,741...43,733,462
Ensembl chr15:43,728,042...43,733,432

G

tropomodulin 2

increases expression

mercuric bromide results in increased expression of TMOD2 mRNA

NCBI chr 9:75,472,903...75,518,620
Ensembl chr 9:75,472,903...75,518,607

G

transmembrane protease, serine 13

increases expression
multiple interactions

mercuric bromide results in increased expression of TMPRSS13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMPRSS13 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:45,230,286...45,258,879
Ensembl chr 9:45,230,398...45,258,879

G

thiol methyltransferase 1A1

increases expression
multiple interactions

mercuric bromide results in increased expression of TMT1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMT1A mRNA

PMID:26272509 PMID:27188386

NCBI chr15:100,201,969...100,227,882
Ensembl chr15:100,202,021...100,226,543

G

transmembrane and tetratricopeptide repeat containing 3

increases expression
multiple interactions

mercuric bromide results in increased expression of TMTC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMTC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:100,279,764...100,323,230
Ensembl chr10:100,279,764...100,323,212

G

transmembrane and tetratricopeptide repeat containing 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TMTC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:123,156,383...123,220,697
Ensembl chr14:123,156,383...123,221,447

G

tumor necrosis factor alpha induced protein 6

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFAIP6 mRNA

NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698

G

tumor necrosis factor receptor superfamily, member 10b

increases expression
multiple interactions

mercuric bromide results in increased expression of TNFRSF10A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:70,004,921...70,021,860
Ensembl chr14:70,004,921...70,021,860

G

tumor necrosis factor receptor superfamily, member 19

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TNFRSF19 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNFRSF19 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:61,201,283...61,284,304
Ensembl chr14:61,201,324...61,283,939

G

tumor necrosis factor receptor superfamily, member 21

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF21 mRNA

NCBI chr17:43,327,446...43,400,079
Ensembl chr17:43,327,446...43,400,080

G

tumor necrosis factor (ligand) superfamily, member 9

increases expression
multiple interactions

mercuric bromide results in increased expression of TNFSF9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:57,412,113...57,414,757
Ensembl chr17:57,412,325...57,414,757

G

TRAF2 and NCK interacting kinase

increases expression
multiple interactions

mercuric bromide results in increased expression of TNIK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:28,317,362...28,724,734
Ensembl chr 3:28,317,363...28,730,007

G

thymocyte selection-associated high mobility group box

increases expression
multiple interactions

mercuric bromide results in increased expression of TOX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TOX mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:6,686,353...6,991,557
Ensembl chr 4:6,686,353...6,991,557

G

trophoblast glycoprotein

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TPBG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:85,724,433...85,729,110
Ensembl chr 9:85,724,433...85,729,093

G

tumor protein D52-like 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TPD52L1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:31,208,369...31,321,989
Ensembl chr10:31,208,372...31,321,954

G

T cell receptor alpha joining 18

increases expression
multiple interactions

mercuric bromide results in increased expression of STK17A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STK17A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:54,438,234...54,438,299
Ensembl chr14:54,438,234...54,438,299

G

T cell receptor alpha joining 19

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA

NCBI chr14:54,437,843...54,437,903
Ensembl chr14:54,437,843...54,437,903

G

trafficking protein particle complex 6A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TRAPPC6A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRAPPC6A mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:19,242,595...19,250,070
Ensembl chr 7:19,242,320...19,250,070

G

T cell receptor beta, constant region 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TRBC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRBC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:41,515,153...41,516,599
Ensembl chr 6:41,515,152...41,516,815

G

tribbles pseudokinase 3

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIB3 mRNA

NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952

G

tripartite motif-containing 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TRIM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIM2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:84,067,746...84,215,659
Ensembl chr 3:84,067,746...84,214,184

G

tripartite motif-containing 38

increases expression
multiple interactions

mercuric bromide results in increased expression of TRIM38 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM38 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:23,962,483...23,975,721
Ensembl chr13:23,953,896...23,975,511

G

tRNA methyltransferase 1 like

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TRMT1L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRMT1L mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:151,304,293...151,333,934
Ensembl chr 1:151,304,293...151,333,912

G

transient receptor potential cation channel, subfamily C, member 4

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TRPC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:54,063,441...54,225,892
Ensembl chr 3:54,063,456...54,225,892

G

transcriptional repressor GATA binding 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TRPS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:50,518,149...50,754,027
Ensembl chr15:50,518,148...50,753,859

G

TSC complex subunit 2

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSC2 mRNA

NCBI chr17:24,814,788...24,851,607
Ensembl chr17:24,814,790...24,851,604

G

Ts translation elongation factor, mitochondrial

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TSFM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSFM mRNA

PMID:26272509 PMID:27188386

NCBI chr10:126,858,201...126,866,683
Ensembl chr10:126,847,441...126,866,709

G

tetratricopeptide repeat domain 39C

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC39C mRNA

NCBI chr18:12,716,168...12,872,461
Ensembl chr18:12,732,953...12,871,920

G

tubulin tyrosine ligase-like family, member 6

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TTLL6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTLL6 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:96,015,283...96,057,008
Ensembl chr11:96,024,612...96,056,277

G

transthyretin

increases expression
multiple interactions

mercuric bromide results in increased expression of TTR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTR mRNA

PMID:26272509 PMID:27188386

NCBI chr18:20,797,266...20,807,383
Ensembl chr18:20,798,337...20,807,378

G

tubulin, alpha 1A

decreases expression

mercuric bromide results in decreased expression of TUBA1A mRNA

NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584

G

twist basic helix-loop-helix transcription factor 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TWIST1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:34,007,670...34,009,830
Ensembl chr12:34,007,670...34,009,828

G

twist basic helix-loop-helix transcription factor 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TWIST2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TWIST2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:91,729,183...91,775,756
Ensembl chr 1:91,729,183...91,775,750

G

thioredoxin reductase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of TXNRD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TXNRD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

G

trypsin domain containing 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of TYSND1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TYSND1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:61,531,279...61,538,552
Ensembl chr10:61,531,293...61,538,552

G

ubiquitin-conjugating enzyme E2Q family-like 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of UBE2QL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2QL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:69,850,951...69,888,016
Ensembl chr13:69,850,951...69,888,008

G

ubiquitin protein ligase E3D

decreases expression
multiple interactions

mercuric bromide results in decreased expression of UBE3D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE3D mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:86,189,364...86,347,003
Ensembl chr 9:86,189,359...86,347,003

G

ubiquitin carboxy-terminal hydrolase L1

increases expression
multiple interactions

mercuric bromide results in increased expression of UCHL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UCHL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:66,833,464...66,844,577
Ensembl chr 5:66,833,434...66,844,577

G

unc-51 like kinase 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ULK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ULK2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:61,666,424...61,750,754
Ensembl chr11:61,666,475...61,745,899

G

unkempt family like zinc finger

increases expression
multiple interactions

mercuric bromide results in increased expression of UNKL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNKL mRNA

PMID:26272509 PMID:27188386

NCBI chr17:25,407,336...25,453,417
Ensembl chr17:25,407,371...25,453,417

G

uroplakin 1A

decreases expression
multiple interactions

mercuric bromide results in decreased expression of UPK1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UPK1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:30,302,517...30,312,159
Ensembl chr 7:30,302,517...30,312,272

G

ubiquitin specific peptidase 28

increases expression
multiple interactions

mercuric bromide results in increased expression of USP28 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:48,896,577...48,953,817
Ensembl chr 9:48,896,675...48,953,817

G

ubiquitin specific peptidase 43

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA

NCBI chr11:67,745,349...67,812,979
Ensembl chr11:67,745,349...67,812,979

G

vesicle-associated membrane protein 7

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP7 mRNA

G

vesicle-associated membrane protein 8

increases expression
multiple interactions

mercuric bromide results in increased expression of VAMP8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAMP8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:72,362,204...72,367,650
Ensembl chr 6:72,362,206...72,367,686

G

vasohibin 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of VASH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VASH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:86,725,474...86,742,462
Ensembl chr12:86,725,474...86,738,865

G

vascular cell adhesion molecule 1

decreases expression
multiple interactions

mercuric bromide results in decreased expression of VCAM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VCAM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

vascular endothelial growth factor A

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEGFA mRNA

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

vestigial like family member 1

increases expression
multiple interactions

mercuric bromide results in increased expression of VGLL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:56,133,466...56,151,900
Ensembl chr X:56,133,466...56,151,900

G

vestigial like family member 3

increases expression
multiple interactions

mercuric bromide results in increased expression of VGLL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:65,612,075...65,663,254
Ensembl chr16:65,612,143...65,663,254

G

vacuolar protein sorting 13C

increases expression

mercuric bromide results in increased expression of VPS13C mRNA

NCBI chr 9:67,747,594...67,905,026
Ensembl chr 9:67,747,678...67,902,920

G

Von Willebrand factor

decreases expression
multiple interactions

mercuric bromide results in decreased expression of VWF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VWF mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:125,529,911...125,663,642
Ensembl chr 6:125,523,737...125,663,642

G

WASP family, member 3

decreases expression
multiple interactions

mercuric bromide results in decreased expression of WASF3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WASF3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:146,317,411...146,410,425
Ensembl chr 5:146,321,795...146,410,425

G

WAP four-disulfide core domain 2

increases expression
multiple interactions

mercuric bromide results in increased expression of WFDC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:164,404,635...164,410,430
Ensembl chr 2:164,404,333...164,410,430

G

WAP four-disulfide core domain 21

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC21P mRNA

NCBI chr11:83,637,766...83,643,472
Ensembl chr11:83,637,766...83,643,468

G

wingless-type MMTV integration site family, member 5A

increases expression
multiple interactions

mercuric bromide results in increased expression of WNT5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT5A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:28,224,962...28,249,405
Ensembl chr14:28,226,707...28,249,405

G

wingless-type MMTV integration site family, member 5B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of WNT5B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:119,409,493...119,521,847
Ensembl chr 6:119,409,492...119,521,308

G

wingless-type MMTV integration site family, member 6

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA

NCBI chr 1:74,793,499...74,824,481
Ensembl chr 1:74,811,051...74,824,481

G

WW domain containing transcription regulator 1

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWTR1 mRNA

NCBI chr 3:57,363,065...57,483,331
Ensembl chr 3:57,363,070...57,483,331

G

X-prolyl aminopeptidase 3, mitochondrial

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of XPNPEP3 mRNA

NCBI chr15:81,284,282...81,341,683
Ensembl chr15:81,284,339...81,341,683

G

tyrosyl-tRNA synthetase 1

increases expression
multiple interactions

mercuric bromide results in increased expression of YARS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YARS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:129,083,595...129,113,033
Ensembl chr 4:129,083,553...129,113,400

G

zinc finger and BTB domain containing 10

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZBTB10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:9,315,627...9,350,393
Ensembl chr 3:9,315,662...9,350,393

G

zinc finger and BTB domain containing 16

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZBTB16 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:48,563,097...48,747,525
Ensembl chr 9:48,565,597...48,747,522

G

zinc finger and BTB domain containing 24

multiple interactions

[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB24 mRNA

NCBI chr10:41,326,354...41,341,578
Ensembl chr10:41,326,379...41,341,570

G

zinc finger, DHHC domain containing 13

increases expression
multiple interactions

mercuric bromide results in increased expression of ZDHHC13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZDHHC13 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:48,438,751...48,477,188
Ensembl chr 7:48,438,751...48,477,188

G

zinc finger E-box binding homeobox 2

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZEB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:44,873,523...45,007,378
Ensembl chr 2:44,873,644...45,007,407

G

zinc finger protein 207

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZNF207 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF207 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:80,274,105...80,299,387
Ensembl chr11:80,274,105...80,296,559

G

zinc finger protein 287

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZNF287 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:62,583,270...62,622,749
Ensembl chr11:62,591,182...62,622,731

G

zinc finger protein 36

increases expression
multiple interactions

mercuric bromide results in increased expression of ZFP36 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:28,076,208...28,078,680
Ensembl chr 7:28,076,209...28,079,678

G

zinc finger protein 385B

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZNF385B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:77,240,966...77,648,050
Ensembl chr 2:77,240,978...77,649,983

G

zinc finger protein 39

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZNF717 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF717 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:58,778,979...58,795,051
Ensembl chr11:58,778,979...58,795,051

G

zinc finger protein 521

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZNF521 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:13,820,070...14,105,812
Ensembl chr18:13,820,070...14,105,844

G

zinc finger protein 750

increases expression
multiple interactions

mercuric bromide results in increased expression of ZNF750 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:121,401,802...121,410,168
Ensembl chr11:121,401,804...121,410,159

G

zinc finger protein of the cerebellum 5

decreases expression
multiple interactions

mercuric bromide results in decreased expression of ZIC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:122,696,572...122,703,127
Ensembl chr14:122,694,207...122,703,089

G

zinc finger matrin type 3

increases expression
multiple interactions

mercuric bromide results in increased expression of ZMAT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZMAT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:32,388,941...32,419,814
Ensembl chr 3:32,388,941...32,420,163

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22182
chemical entity	22181
group	22077
polyatomic entity	22077
heteroatomic molecular entity	22005
coordination entity	15231
zinc group coordination entity	10170
mercury coordination entity	4995
mercury dibromide	1013
Path 2
Term	Annotations
CHEBI ontology	22182
subatomic particle	22174
composite particle	22174
hadron	22174
baryon	22174
nucleon	22174
atomic nucleus	22174
atom	22174
metal atom	18886
transition element atom	17962
d-block element atom	17952
zinc group element atom	12239
mercury atom	6817
mercury molecular entity	6817
mercury coordination entity	4995
mercury dibromide	1013

paths to the root